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Abstract 
This thesis aimed to identify biomarkers which could be used to determine the 
biological behaviour of canine mast cell tumours. The rationale for this was that 
there is a relative paucity of objective biomarkers, which can be established 
without the need to perform an act of surgery. In order to do this, the potential 
array of biomarkers available were reviewed. It was considered that markers 
attainable by interrogation of a blood sample may be most appropriate to fulfil 
the identified need. After positive results in human oncology, the first analyses 
focused on the relationships between routinely measured parameters, both 
proteins (the AGR) and leukocytes (the neutrophil to lymphocyte ratio). Blood 
samples were taken from dogs with mast cell tumours prior to any treatment 
intervention. The neutrophil to lymphocyte ratio was identified as a biomarker 
which could identify canine mast cell tumours with an aggressive biological 
behaviour.  
Building a hypothesis from results in both veterinary and human oncology it was 
thought that further analysis of the serum proteome could identify further 
biomarkers of interest. Using the same blood samples, one-dimensional serum 
protein electrophoresis identified that dogs with biologically aggressive mast cell 
tumours had more significantly increased α-2 protein concentrations than those 
with LG mast cell tumours.  In an attempt to identify which specific proteins 
were responsible for changes in the proteome between dogs with mast cell 
tumours and also when compared to health control dogs, two dimensional serum 
protein electrophoresis was then performed. Twelve proteins were identified in 
dogs with aggressive mast cell tumours and not in healthy controls. Some of 
these proteins are acute phase proteins, reflecting the inflammatory nature of 
this neoplasm. Others are protease inhibitors which may have a role in tumour 
pathogenesis. This research has identified biomarkers, which with further 
validation could have a role in identifying tumours likely to have a severe effect 
on dogs’ quality of life and allow prompt treatment. It has also identified areas 
for future research.  
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1 Introduction 
1.1 Mast Cells and Mast Cell Tumours 
Mast cells are granular leukocytes which are involved in type I hypersensitivity 
reactions and are part of the innate immune system (Day and Shultz, 2010). Mast 
cells arise from multipotential haematopoietic stem cells within the bone 
marrow and complete maturation within their destination organ (Kitamura and 
Fujita, 1989). For this reason, mast cells are often normally identifiable in the 
circulation of healthy animals (Welle et al ., 2008). The mast cell’s cytoplasm 
has many granules, containing a number of vasoactive substances including 
histamine, heparin, eosinophilic chemotactic factor, metabolites of arachidonic 
acid (leukotrines) and proteolytic enzymes which are released on activation of 
the cell (Dobson and Scase, 2007; Welle et al ., 2008). Two distinct forms of 
mast cells, with different properties, are found in the dog, mucosal (found 
mainly in the intestine and lung) and connective tissue (found in the connective 
tissues and skin). Mucosal mast cells generally have greater concentrations of 
histamine, contained in larger numbers of granules and have a longer life span of 
up to six months, whereas connective tissue cells usually live less than 40 days 
(Tizard, 2004).  
Mast cells express a number of high affinity receptors for the Fc region of 
immunoglobulin E (IgE). When an allergen (antigen) binds to the IgE, the 
crosslinking of two IgE molecules results in activation of the cell and massive 
degranulation (Tizard, 2004; Day and Shultz, 2010), although a lower level or 
‘piecemeal’ degranulation can also be caused by lipopolysaccharides, 
endothelins, neuropeptides, adenosine, trauma, heat and toxins (Tizard, 2004; 
Dobson and Scase, 2007). The release of the substances within granules can 
cause a wide range of both local and systemic effects (Welle et al ., 2008). 
Activation of the mast cell also results in production of an array of cytokines and 
chemokines which promote a Th2 and/or pro-inflammatory response from the 
immune system. These include IL-4, IL-5, IL-6, IL-13, IL-16, TNF-α and CCL-3 
(Wilson et al ., 2000; Wernersson and Pejler, 2014).  
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Neoplastic transformation of mast cells can occur at many sites. The skin is the 
most common location in the dog (Blackwood et al ., 2012). Subcutaneous and 
less frequently, primary oral, gastrointestinal, urethral, spinal, laryngeal, 
salivary gland, pulmonary and nasopharyngeal mast cell tumours (MCT) have 
been described, (London and Thamm, 2012; Campbell et al ., 2017).  
1.1.1. Incidence and Prevalence 
In a population of insured dogs in the UK, the incidence of MCTs was 126 per 
100,000 dogs per year, the second most common cutaneous malignancy. This 
population was skewed towards younger animals and the figure including dogs of 
all ages may be higher (Dobson et al ., 2002). Within another population of over 
100,000 insured dogs in England the prevalence of MCT was 0.27% (Shoop et al., 
2015). 
1.1.2. Signalment 
Certain breeds linked by a common ancestry have an increased relative risk for 
developing MCTs with Boston terriers, boxers and English bulldogs having a 
relative risk of 14 of developing MCTs compared to all other breeds (Peters, 
1969).  Labrador retrievers, pugs, golden retrievers and the mastiff and terrier 
phylogenetic cluster (White et al ., 2011; Warland and Dobson, 2013; Shoop et 
al., 2015) also have an increased risk; some other breeds have a reduced risk: 
English springer spaniels, English cocker spaniels, German shepherd dogs, West 
Highland white terriers, Border collie and cavalier King Charles spaniels (Warland 
and Dobson, 2013; Shoop et al ., 2015). An increased odds ratio for neutered 
females developing MCTs has been reported (White et al ., 2011), although 
numerous other reports showed no gender predisposition (Welle et al ., 2008). 
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1.1.3. Aetiology 
Although the precise genetic aetiology of most MCTs is not known, in recent 
years, aberrations of the cellular oncogene c-Kit and transcribed protein KIT 
have been implicated in approximately 14-26% of MCTs (Zemke, Yamini and 
Yuzbasiyan-Gurkan, 2002; Webster et al., 2006; Letard et al., 2008).  
KIT is a class III receptor tyrosine kinase (TK) which, in normal cells, is activated 
by binding of its ligand- stem cell growth factor (SCGF) (Abu-Duhier et al ., 
2003). KIT is present in numerous normal cell types and activation of the 
tyrosine kinase leads to proliferation, maturation, migration and survival of 
normal mast cells and their stem cells (Ma et al ., 1999). KIT expression on 
malignant mast cells was first noted by flow cytometric analysis (London et al . 
1996) and dysregulation and constitutive activation in MCTs have been heavily 
investigated as an aetiopathogenic factor.  
Constitutive activation of KIT in MCTs is usually a result of mutation of the c-kit 
proto-oncogene, often within the juxtamembrane coding region   (Ma et al ., 
1999). Numerous c-Kit mutations have been identified: deletions, insertions or 
single base pair alterations (Zemke, Yamini and Yuzbasiyan-Gurkan, 2002).  
In a population of 191 dogs with MCT, 32 of 50 mutations detected in the c-kit 
oncogene were in the juxtamembrane domain, within exon 11 (Letard et al ., 
2008). Other mutations within exons 2, 5, 6, 7, 8, 9, the junction of 9 and 10, 15 
and 17, and coding for various other sections of the KIT protein have also been 
identified (Letard et al ., 2008; Takeuchi et al ., 2013). In 13 of 47 (27.7%) MCTs 
with previously identified activating c-kit mutations, 8 were internal tandem 
duplications (ITD) on exon 11 (all of which were different), but the functional 
significance of a further 21 of these mutations was unknown (Takeuchi et al ., 
2013). 
Given the relatively low percentage of MCT with known activating c-kit 
mutations, other as yet unknown factors must also be involved in the aetiology 
of MCTs (Blackwood et al ., 2012).  
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1.1.4. Presentation 
Cutaneous MCTs can develop at any location and 11-14% of affected dogs present 
with multiple masses (Mullins et al ., 2006). Based on their gross appearance, 
two distinct cutaneous forms have been reported to exist:  
- Well differentiated tumours; slow growing and hairless (Figure 1-1). 
- Poorly differentiated tumours; ulcerated, rapidly growing and pruritic 
(Figure 1-2) (Blackwood et al ., 2012). 
It can often be difficult to categorise tumours in this manner however as MCTs 
have an extremely varied appearance (Blackwood et al ., 2012; London and 
Thamm, 2012).  
  
18 
 
 
 
 
 
 
 
 
Figure 1-1: Typical appearance of a low grade cutaneous mast cell 
tumour. There is minimal erythema, oedema and the mass is under 1cm 
in size. This mass is situated on the dorsum of a Labrador retriever. 
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Figure 1-2: Typical appearance of a high grade cutaneous mast cell 
tumour. There is erythema, oedema and ulceration. This mass is situated 
on the lateral elbow of a miniature schnauzer. 
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Both local and systemic clinical signs can be associated with MCTs as a result of 
mast cell degranulation (Welle et al ., 2008).  The wide range of clinical signs 
reflect the diverse nature of the granules and their normal function.  Examples 
of local signs include pruritus, erythema, oedema and swelling. Systemic signs 
include: vomiting, diarrhoea, gastrointestinal ulceration, lethargy, a reduced 
appetite, paroxysmal sneezing following cutaneous trauma, fever, impaired 
coagulation due to heparin release and collapse (Howard et al ., 1969; Welle et 
al ., 2008; Blackwood et al ., 2012).  
The activation of H2 receptors within the stomach causes increased release of 
acid into the gastric lumen resulting in many of the gastrointestinal signs. Dogs 
with MCT with gastrointestinal signs refractory to H2 blocking treatment have 
increased plasma histamine concentrations (Ishiguro et al., 2003). 
Gastrointestinal ulceration was identified on necropsy of 20 of 24 dogs with MCTs 
(Howard et al ., 1969). Up to half of dogs with MCTs have paraneoplastic clinical 
signs (Welle et al ., 2008) and 12 of 14 dogs with a cutaneous MCT and bone 
marrow spread had systemic clinical signs possibly attributable to degranulation 
(Marconato and Bettini, 2008).  
1.1.5. Diagnosis  
Cytological diagnosis of MCTs is accurate, with 96% of MCTs correctly diagnosed 
(Baker-Gabb, Hunt and France, 2003). Mast cells are identifiable by the presence 
of metachromatically staining cytoplasmic granules (Blackwood et al ., 2012), 
easily seen with routine haematological stains such as Leishman, but also with 
rapid, modified Romanowsky-type stains such as Diff Quik™ (Welle et al ., 2008). 
Occasionally, toluidine blue and Wright-Giemsa may need to be used to identify 
granules (London and Thamm, 2012) particularly for MCTs containing few 
granules, however, these tumours are also difficult to categorise 
histopathologically (London and Thamm, 2012). 
21 
 
 
 
Investigation of a possible MCT requires definitive diagnosis, variable degrees of 
clinical staging and identification of any paraneoplastic signs (Welle et al ., 
2008). If a MCT is diagnosed cytologically and there are either additional 
negative prognostic indicators or the mass is not amenable to wide excision, it is 
recommended that the diagnostic protocol is expanded to include full clinical 
staging (Welle et al ., 2008).  
1.1.6. Clinical Staging  
There are consensus recommendations for whether  full clinical staging 
(evaluation of a cancer patient in order to determine the extent of the local 
disease and presence of any distant metastasis) should be carried out in an 
individual MCT case (Blackwood et al ., 2012). Full staging prior to surgery is not 
recommended for MCTs where the tumour appears easily resectable and does 
not have accompanying negative prognostic indicators. Full staging in MCTs 
historically involved haematological and biochemical profiles, buffy coat 
analysis, cytological lymph node assessment, abdominal ultrasound with 
cytological assessment of liver and spleen, thoracic radiographs and bone 
marrow biopsy (London and Thamm, 2012).  
Buffy coat analysis is no longer recommended since mastocytaemia may occur in 
dogs with several other clinical conditions. The number of mast cells per buffy 
coat smear was found to be lower in dogs with MCTs than with other clinical 
conditions (McManus, 1999).  
Thoracic imaging is recommended as a part of complete staging in the most 
recent consensus document regarding MCT (Blackwood et al., 2012). Since this 
publication, an evaluation of 230 dogs with MCT and thoracic imaging identified 
none with thoracic metastasis, although metastatic spread from another 
unrelated tumour was identified in two cases (Warland et al ., 2014). Infrequent 
thoracic metastases have however been previously identified (Welle et al ., 
2008). Thoracic imaging may also be useful for evaluation of the intra-thoracic 
lymph nodes which may drain the skin in the cranial half of dogs with MCT.  
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Due to the potential for the identification of metastasis, cytological sampling of 
palpably normal or abnormal draining lymph nodes is currently advocated for 
cases with a confirmed MCT (Blackwood et al ., 2012; London and Thamm, 
2012). Abdominal ultrasound with fine needle aspirate (FNA) of the liver and 
spleen is recommended for cases with nodal metastasis (Blackwood et al ., 
2012). However, metastatic disease to the liver and spleen can be identified in 
the absence of nodal metastasis, so there may be a role for abdominal 
ultrasound in all cases of MCT (Pizzoni et al ., 2017). The sensitivity of visible 
ultrasound changes for detecting splenic and hepatic infiltration of MCT was 42% 
and 0% respectively in a population of dogs with clinically aggressive MCT (Book 
et al., 2011). The prognosis for dogs with metastasis to either organ was worse 
than those without metastasis (Book et al ., 2011).  
Since normal mast cells may be present within the cytological samples from 
lymph node, liver and spleen of healthy dogs, there are currently no robust 
guidelines for diagnosis of metastasis using these methods. Criteria have 
included the presence of sheets of mast cells; more than two high powered 
fields containing increased numbers of MCTs; a large number or poorly 
differentiated mast cells; over 50% mast cells in the sample; several aggregates 
of mast cells seen and/or if poorly differentiated mast cells are seen (Gieger et 
al ., 2003; Cahalane et al ., 2004; Thamm, Turek and Vail, 2006; Stefanello et al 
., 2009; Baginski, Davis and Bastian, 2014). Others have not documented their 
diagnostic criteria (LaDue et al ., 1997; Thamm, Mauldin and Vail, 1999; Sfiligoi 
et al ., 2005). The University of Pennsylvania Clinical Pathology Service has 
formulated diagnostic criteria, with ‘certain metastasis’ defined as: ‘On at least 
one slide, effacement of lymphoid tissue by mast cells, and/or the presence of 
aggregated, poorly differentiated mast cells with pleomorphism, anisocytosis, 
anisokaryosis, and/or decreased or variable granulation, and/or greater than 
five aggregates of more than three mast cells’ (Krick et al ., 2009). When 
considering histopathological identification of lymph node metastasis, staging 
criteria are available in a four-tiered classification system, with advancing stage 
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found to be a poor prognostic indicator (Weishaar et al ., 2014). This grading 
system has not currently been applied to cytological examination. 
1.1.7. Treatment 
The diverse biological activity of MCTs has resulted in the routine use of a 
number of treatment options although surgery, radiotherapy and chemotherapy, 
either as single treatments or in combination are the usual treatment modalities 
(Welle et al ., 2008; London and Thamm, 2012). Intralesional and systemic 
corticosteroids, immunotherapy, intraregional deionised water, hypothermia, 
photodynamic therapy, cryosurgery and electrochemotherapy have also been 
used (Blackwood et al ., 2012; Lowe et al ., 2016; Case and Burgess, 2018). 
Treatments are selected dependent on the presence or absence of negative 
prognostic factors (London and Thamm, 2012), with treatment algorithms 
available upon which to base these decisions (Blackwood et al ., 2012; London 
and Thamm, 2012).  Paraneoplastic conditions should also be treated, most 
frequently with antihistaminic agents, blocking both H1 and H2 receptors. Anti-
inflammatory doses of corticosteroids are also frequently used in the treatment 
of paraneoplastic signs. 
1.2 Prognostic factors 
1.2.1. Non-histopathological markers 
In order to obtain a histopathological diagnosis prior to treatment, incisional or 
punch biopsies are required. This approach is often avoided with mast cell 
neoplasia due to concerns over mast cell degranulation leading to poor wound 
healing (O’ Keefe, 1990; Dobson and Scase, 2007; Welle et al ., 2008; London 
and Thamm, 2012). Five of twelve biopsy procedures of MCTs resulted in delayed 
healing, although incomplete resection was not associated with poorer results 
than complete excision or with removal of a benign neoplasm (Killick et al ., 
2011). 
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A number of factors have therefore been examined for their ability to predict 
the biological behaviour of MCTs prior to attaining a histopathological grade. It is 
recommended that the presence or absence of these factors is used to guide 
treatment and staging decisions prior to surgery (Blackwood et al ., 2012).  
1.2.1.1. Gross appearance/Clinical signs 
Gross tumour appearance has been suggested to correlate with biological 
behaviour of MCTs, with rapid growth, local irritation/inflammation, local 
infiltration/poor demarcation, ulceration, satellite nodules, pruritus and 
paraneoplastic signs all being indicators of a more aggressive disease course 
(Thamm, Mauldin and Vail, 1999; Mullins et al ., 2006; London and Thamm, 
2012). MCTs which have been present for more than 28 weeks have resulted in a 
better prognosis after removal than those present for less time (Bostock, 1973). 
Despite this, tumours which appear without aggressive features may still have a 
high biological activity (Blackwood et al ., 2012). 
The presence of clinical signs related to the tumour such as gastrointestinal 
signs, pain, ulceration or oedema also correlate with a less favourable outcome 
(Mullins et al ., 2006). 
1.2.1.2. Tumour location 
MCTs of the scrotum and testes have a significantly shorter disease free interval 
(DFI) than those in other locations (Sfiligoi et al ., 2005) and it is suggested that 
those in the subungual area and other mucocutaneous sites result in a poorer 
prognosis (London and Thamm, 2012). MCTs of the muzzle are more likely to be 
of a higher histopathological grade and to metastasise than those in other 
locations (Gieger et al ., 2003).  
1.2.1.3. Clinical stage   
The World Health Organisation (WHO) Clinical Staging System for MCTs (Table 1-
1) (Owen, 1980) correlates with biological behaviour in a number of studies 
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(Bostock, 1973; Turrel et al., 1989; Gerritsen et al., 1998; Sfiligoi et al., 2005). 
This may not be applicable to all locations (Gieger et al., 2003) and the 
presence of multiple tumours (stage III) does not reliably result in a worse 
prognosis (McNiel, Prink and O’Brien, 2006; Mullins et al ., 2006; Murphy et al ., 
2006; Scase et al ., 2006; Thamm, Turek and Vail, 2006; Maglennon et al ., 
2008).  It is thought that multiple canine MCTs are likely to represent de novo 
masses rather than metastatic spread (Amagai et al ., 2013).  
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WHO stage Definition 
0 One tumour in the skin incompletely removed, with no lymph 
node involvement. 
I One tumour in the skin, with no regional lymph node 
involvement 
II One tumour in the skin with regional lymph node involvement 
III Multiple large, deep skin tumours, with or without lymph node 
involvement 
IV Any tumour with distant metastasis or recurrence with 
metastasis 
Table 1-1: World Health Organisation staging guidelines 
for dogs with cutaneous mast cell tumours (Owen, 1980). 
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Lymph node metastasis, when treated, also results in similar survival times as 
dogs with stage 0 disease (Chaffin and Thrall, 2001; Thamm, Turek and Vail, 
2006).  LaDue et al . (1997) showed no association with either lymph node 
metastasis or clinical stage on DFI or survival in irradiated, incompletely excised 
MCTs. However, if lymph nodes are evaluated histopathologically, lymph node 
metastasis is associated with a poorer prognosis (Weishaar et al ., 2014). 
1.2.1.4. Age  
Increasing age is associated with increasing odds of developing distant 
metastasis (Kiupel et al ., 2005) and decreased survival time after MCT surgery 
(Michels et al ., 2002) with dogs over eight years having a reduced median 
survival time (MST) compared to those under eight (Sfiligoi et al ., 2005). These 
studies did not investigate tumour related death however and co-morbidities are 
more likely with increasing age.  
1.2.1.5. Sex    
Male dogs have been reported as having shorter survival times than females 
(Gerritsen et al ., 1998; Kiupel et al ., 2005).  
1.2.1.6. Breed 
Boxers (Bostock, 1973) and pug dogs (McNiel, Prink and O’Brien, 2006) generally 
have a higher frequency of lower grade tumours despite frequently having 
multiple MCTs and would therefore be expected to have a better prognosis in 
general. Conversely, Shar-Peis have been associated with MCT with a higher 
biological activity and an expected poorer prognosis (Miller, 1995). 
1.2.1.7. Cytology 
Different cytological characteristics have been used in an attempt to stratify 
MCTs into groups with different expected biological behaviours, with varying 
success. With one grading system, only three of six grade III tumours were 
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correctly classified (Nieto, 2009). However, use of another cytological grading 
system was more successful, with 94 percent of samples correctly classified 
when compared to histological grade using  cytology alone (Scarpa, Sabattini and 
Bettini, 2014).  This system identified features present in the two-tiered 
histopathological system, but on a cytological sample, analysing a minimum of 
1000 cells. This technique was later repeated with the same proportion of 
tumours correctly classified (Hergt et al., 2016). Both of these analyses resulted 
in the misclassification of a small proportion of HG MCT as LG, resulting in the 
conclusion that this cytological method is inadequate (Hergt et al., 2016).  
Another system was created, using either poor granulation of tumour cells or 
two of four of the following criteria: mitotic figures, binucleated or 
multinucleated cells, nuclear pleomorphism, or >50% anisokaryosis. This system 
had 88% sensitivity and 94% specificity for identifying the correct 
histopathological grade (Camus et al ., 2016). Nuclear morphometry can also be 
used to grade MCTs from a cytological sample with promising results (De 
Strefezzi et al . 2009), although again this technique is not widely used. 
Argyrophilic staining of nucleolar organising regions (AgNOR) staining can also be 
used  on cytological specimens and resulted in accurate prediction of 
histopathological grade (Kravis et al ., 1996).  
1.2.2. Histopathological prognostic factors. 
1.2.2.1. Histopathological Grade 
Due to the variability in both the appearance and behaviour of MCTs, prognostic 
markers are crucial to predict the biological behaviour and guide treatment 
protocols. Although cytology offers a means of diagnosis, histopathological grade 
is currently the most objective method for determining the prognosis in a dog 
with a MCT.  
The first mast cell tumour grading system was proposed and evaluated using the 
following criteria: the ratio between diameter of nucleus and total diameter of 
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the cell, the frequency of mitotic figures, the degree of cellular pleomorphism, 
the discreteness of the tumour cells, and the cellularity of the tumour as well as 
the nature of the intracytoplasmic metachromatic granules (Bostock, 1973). 
Grade I tumours were the most biologically active tumours and designated as 
poorly differentiated tumours. However, few objective criteria were used. 
Grading was based on subjective assessment such as the criteria of ‘mitotic 
figures were seen, sometimes very frequently’. Using this grading system there 
was a significant difference in survival times in grade III MCT dogs compared to 
this with grade I or II.  
Subsequent to this, a different three-tiered system based on the degree of tissue 
invasion was used for MCT (Patnaik, Ehler and Macewen, 1984). This grading 
system designated grade I tumours as having the least aggressive biological 
behaviour and grade III the most aggressive. This grading system also contains 
subjective elements and resulted in greater than 50% of tumours being 
designated as grade II tumours. The majority of dogs (84%) with grade II mast 
cell tumours treated with surgery alone remained free of mast cell disease, 
however 5%-56% of dogs die due to their MCT (Patnaik, Ehler and Macewen, 
1984; Séguin et al ., 2001). This three tiered grading system resulted in 
significantly different survival times between grades (Patnaik, Ehler and 
Macewen, 1984). 
Using an alternative two-tiered grading system (Kiupel et al . 2011), dogs were 
designated as having high grade (HG) or low grade (LG) MCTs. Dogs with HG 
MCTs treated with surgery alone had a MST of under four months whereas those 
with LG MCTs had an MST in excess of two years. Criteria classifying a MCT as HG 
with this system are over seven mitotic cells per ten high powered fields (HPF) 
or three or more multinucleated (more than three nuclei) cells in ten HPF or 
three or more bizarre nuclei per ten HPF.  
The usefulness of the newer system has been validated in the original report and 
independent publications subsequent to its introduction. LG and HG MCTs 
resulted in a significantly different 1452 and 208 day survival times although 
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treatments were not standardised between groups (Takeuchi et al ., 2013). The 
two-tiered system has less inter-observer variation and greater concordance 
amongst pathologists as well as a greater prognostic significance (Kiupel et al ., 
2011; Vascellari et al ., 2013; Sabattini et al ., 2014). 
A number of tissue biomarkers have been assessed for their potential use in 
predicting biological behaviour in MCTs.  
1.2.2.2. Mitotic Count 
Mitotic count (MC) is defined as the number of mitotic cells seen in ten 
consecutive high powered fields (400x) while mitotic index is defined as the 
number of mitotic cells divided by the number of cells not in mitosis (Meuten, 
Moore and George, 2016). Veterinary pathology studies often incorrectly refer to 
the MC as mitotic index. In this thesis, the term MC will be used, but in 
references, ‘mitotic index’ may be used incorrectly. MC has consistently been 
associated with the biological behaviour of canine cutaneous MCTs, both when 
considered as a linear scale and when values above and below a threshold value 
are used.  
The two tiered histopathological grading system for MCTs (Kiupel et al ., 2011) 
used MC as one of the elements which can determine the grade. Tumours with a 
MC of at least seven (evaluating the most mitotically active areas), are 
considered HG although since other non-mitotic factors can also define HG 
status, tumours with a MC of less than seven may also be considered HG.  
The three tiered histopathological grading system also considers the number of 
mitoses, but only in a single high powered field (Patnaik, Ehler and Macewen, 
1984); Grade I having no mitotic figures; grade II as zero to two mitoses per high 
powered field; and grade III as three to six. Numerous other factors such as 
tissue invasion influence this grading system, perhaps explaining why mitotic 
index was not significantly different between the three grades of cutaneous MCT 
in one report (Sakai et al ., 2002). When the areas of greatest proliferation were 
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assessed, a cut off value of five mitotic figures per ten high powered fields was 
predictive of three tiered grade and also outcome for dogs with a grade II 
tumour (Romansik et al ., 2007).  
When high power fields were selected at random, there was no significant 
difference in survival between dogs with a MC of 0-4 and those with a count of 5-
10, although the risk of MCT related death was increased in those with a count 
above 10 (Bostock et al ., 1989). A cut off value of five for MC was predictive of 
all-cause mortality within the study period, although the method of assessing the 
MC was not reported (Vascellari et al ., 2013) 
When fields were selected according to those with highest mitotic rate, MC was 
strongly predictive of survival, mast cell related death and/or development of 
metastatic disease leading to proposals for both a two tiered (zero to five and 
greater than five) and two differing three tiered (zero, one to seven and greater 
than seven; zero or one, two to seven and greater than seven) systems 
(Romansik et al ., 2007; Elston et al ., 2009; van Lelyveld et al ., 2015) to 
predict behaviour. A two tiered MC system with a cut off value of five was highly 
specific (96%) but insensitive (32%) for MCT related death while a cut off value 
of two was 80% specific and 76% sensitive (van Lelyveld et al ., 2015). 
The lack of agreement amongst pathologists as to the optimal stratification 
system and method of assessing MC result in a very confusing picture for the 
clinical practitioner. This is further confounded by studies which report different 
prognostic indices and differences as to whether dogs given adjuvant treatment 
are included in survival analyses. It is however evident that MC is a measure of 
biological activity and is likely to be a prognostic factor.  
1.2.2.3. KIT 
KIT is the protein expressed by the c-kit oncogene. It has been hypothesised that 
due to its role in tumour development, differences in the staining pattern of KIT 
between grades of tumour might predict survival of dogs with MCTs. In less 
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biologically active tumours overproduction of ligand of KIT (stem cell factor) by 
different cells could induce tumour formation by overstimulation of KIT. In more 
biologically active tumours, mutations of c-kit could lead to constitutive 
activation of the receptor (Reguera et al ., 2000).  
The manner in which the KIT protein is distributed in the cell on 
immunohistochemical staining has been formally described as three distinct 
patterns; a membrane-associated staining (type I) also found in non-neoplastic 
mast cells; a focal to stippled cytoplasmic staining with decreased membrane-
associated staining (type II); and a diffuse cytoplasmic staining (type III) (Kiupel 
et al., 2004). Tissue microarray was performed to quantify expression of KIT 
protein, but this was not associated with KIT protein localisation (Webster et al 
., 2006). An intracytoplasmic pattern (type II or III) is associated with a worse 
outcome and greater propensity for tumour recurrence after surgical resection 
suggesting that the cytoplasmic form may contain activating mutations, which 
confer a more aggressive phenotype (Webster et al ., 2004; Patruno et al ., 
2014). Type III KIT staining pattern was associated with a shorter DFI and overall 
survival in dogs with MCTs treated with surgery and chemotherapy with or 
without radiotherapy treatment (Webster et al ., 2008). A correlation between 
KIT staining and prognosis has not been found universally (Bergman et al . 2004). 
Mutation of c-Kit has been linked with biological behaviour of Patnaik graded 
MCT. However, the presence of any activating mutation was not related to 
overall survival time, suggesting that different mutations may result in different 
levels of activation of the tyrosine kinase depending on their location (Takeuchi 
et al ., 2013). Four of six grade III MCTs contained mutated c-Kit; eight of 58 
grade II tumours showed juxtamembrane mutations of c-Kit while none of 
twenty-four grade I tumours were mutated. Duplications were most often 
associated with higher grade tumours (Zemke, Yamini and Yuzbasiyan-Gurkan, 
2002). In contrast, no correlation was found between c-Kit mutational status and 
tumour grade using the two tier grading system (Takeuchi et al ., 2013).  
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ITDs on exon 11 (juxtamembrane region) of c-Kit have been consistently 
associated with a poorer prognosis, significantly shorter MST and DFI, an increase 
in MCT recurrence after surgery, and MCT related death. ITDs on exon 11 were 
found only in grade III neoplasms or were predictive of histopathological grade 
and were also associated with an intracytoplasmic KIT immunohistochemical 
staining pattern (Webster et al ., 2006, 2008; Takeuchi et al ., 2013). Presence 
of ITDs was not an independent prognostic factor in a multivariable model, but 
the number of cases was low (eight) (Takeuchi et al ., 2013). ITDs affecting exon 
eleven may therefore be the most functionally significant c-kit mutations in 
MCTs. 
Phosphorylated (activated) KIT identified using immunohistochemistry may be a 
prognostic determinant in canine mast tumours (Thompson et al ., 2015). This 
was substantiated by a further study (Morini et al ., 2004) however in spite of 
this, c-Kit score was not found to correlate with mast cell grade (Bergman et al . 
2004).  
1.2.2.4. Ki67 
Ki67 is a nuclear protein involved in the transcription of ribosomal RNA, 
expressed during the cell cycle but not in cells which are not cycling (Bullwinkel 
et al ., 2006). The Ki-67 index is therefore a measure of the proportion of cells 
in cell cycle  i.e. the proliferation rate (Vascellari et al ., 2013). Ki-67 index 
correlates well with bromodeoxyuridine uptake which is considered an accurate 
index  of proliferation indicating Ki67 can also be considered a ‘gold standard’ 
proliferation marker (Sakai et al ., 2002). This marker is often reported as a 
percentage of cells with positive immunohistochemical staining (Scase et al., 
2006), although some report it as positive nuclei in 1000 cells (Abadie, 
Amardeilh and Delverdier, 1999). Ki67 staining has been examined extensively in 
MCTs using a variety of assessment methods (Abadie, Amardeilh and Delverdier, 
1999; Sakai et al ., 2002; Scase et al ., 2006; Maglennon et al ., 2008; Vascellari 
et al ., 2013; Berlato et al ., 2015; van Lelyveld et al ., 2015). 
34 
 
 
 
A Ki-67 score above a designated threshold has been identified as an 
independent prognostic variable for dogs with cutaneous MCTs (Abadie, 
Amardeilh and Delverdier, 1999; Vascellari et al ., 2012). A high Ki-67 (using 
tumours assessed by different laboratories- but using each laboratory’s cut-off 
value) is a sensitive predictor for MCT related death, but is not specific (van 
Lelyveld et al ., 2015). When animals with a low MC (<2) were evaluated, Ki-67 
was found to be predictive of survival,  although mortality rate for dogs with low 
MC, high Ki67 MCT was less than 20% (van Lelyveld et al ., 2015). Dogs with a 
high MC and a low Ki-67 were found to have a lower mortality rate than those 
with a high MC and high-67 (van Lelyveld et al ., 2015). Despite this, Ki-67 is not 
as useful a negative prognostic factor as a high histopathological grade (three 
tiered system) and in a different population of dogs, did not have additional 
benefit to MC- which can be attained with no additional cost (Berlato et al ., 
2015). 
Ki-67 proliferation index is significantly different between grade I and II and also 
between grade II and III MCTs (Sakai et al ., 2002). Ki-67 can also successfully 
stratify grade II tumours (three tiered grading system) into those with a higher 
and lower biological activity, which had previously been a problem (Abadie, 
Amardeilh and Delverdier, 1999; Scase et al ., 2006; Maglennon et al ., 2008; 
Berlato et al ., 2015). This application has been made less useful by the two 
tiered grading system, which is now in widespread use. However, Ki-67 
expression correlates with Kiupel’s grading system as well as survival, using a Ki-
67 threshold of 10.6 after receiver operating characteristic (ROC) curve analysis 
(Vascellari et al ., 2013).  
A flaw in many immunohistochemical biomarkers, but particularly Ki-67, is that 
the quantitative method of assessment and cut-off-value are not standardised 
between pathologists. This suggests a need for standardisation, or a requirement 
for each laboratory to calibrate its own cut-off value. 
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1.2.2.5. Proliferating nuclear cellular antigen 
Another proliferation marker explored in relation to prognosis of MCTs in dogs is 
proliferating nuclear cellular antigen (PCNA), a member of the DNA sliding clamp 
family (Scase et al ., 2006). The concentration of this protein increases markedly 
in the S or synthesis phase of cellular division (Bravo and Macdonald-Bravo, 
1985).  The PCNA score in five HPFs was higher in recurrent MCTs compared to 
non-recurrent MCT (Simoes, Schoning and Butine, 1994).  A shorter survival time 
was demonstrated in tumours with a PCNA score above the median than those 
with a score below. The number of positively stained cells correlated with MC 
but performing the stain was more technically demanding than other 
immunohistochemical methods. This fact combined with later studies that failed 
to demonstrate a correlation between PCNA score and survival, put into question 
the utility of this biomarker in canine MCTs (Abadie et al . 1999, Scase et al . 
2006). 
1.2.2.6. Argyrophilic staining of nucleolar organising regions 
Argyrophilic staining of nucleolar organising region (AgNOR) describes a 
technique whereby a silver stain detects sites of transcription for RNA in the 
cell’s nucleus, visible as small nuclear foci (Trerè, 2000). 
AgNOR has been assessed as a potential prognostic factor in biopsied and excised 
MCT (Bostock et al ., 1989; Simoes, Schoning and Butine, 1994; Kravis et al ., 
1996; Scase et al ., 2006; Webster et al ., 2007). AgNOR count correlates with 
histopathological grade in some human neoplasms (Bostock et al ., 1989) and 
indicates the rate of cell cycle progression (generation time) in dogs (Webster et 
al ., 2007).  
Early work in  canine MCT suggested AgNOR count better predicts survival and 
recurrence than using MC or histopathological grade alone (Bostock et al ., 
1989). AgNOR count was found to be a good indicator of three month non-
recurrence of excised MCTs (Simoes, Schoning and Butine, 1994).  AgNOR score 
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combined with Ki-67 can indicate both generation time and proliferation rate 
(Webster et al ., 2007). When a number of proliferation indices and KIT 
mutations were investigated in relation to mast cell stage, only AgNOR was 
found to be significantly associated with a more advanced WHO stage (stage II 
over stage I) which has previously found to be prognostic (Krick et al ., 2009, 
2017; Weishaar et al ., 2014). However, AgNOR count was not correlated with 
another proliferation marker (PCNA) (Simoes et al . 1994). 
There has not been a standardised method for performing this staining technique 
and as a result, any laboratory wishing to perform this stain has previously had 
to perform its own validation. A human standardisation system (Trerè, 2000) was 
used by Scase et al . (2006) but AgNOR was not able to predict survival 
independent of the histopathological grade, contradicting Bostock’s earlier work 
and suggesting limited use for AgNOR count as a prognostic biomarker. 
1.2.2.7. Minichromosome maintenance protein 
Minichromosome maintenance proteins are required for DNA replication and are 
present throughout all phases of the cell cycle but are reduced during 
differentiation, quiescence and senescence (Berlato et al ., 2012).  They are 
considered a more accurate measure of whether a cell is dividing than other cell 
cycle dependent biomarkers (Laskey, 2005) and  multivariate analysis of canine 
MCTs has shown that expression of minichromosome maintenance protein 7 
(MCM7) significantly correlates with prognosis (Berlato et al ., 2012). Dogs with a 
MCM7 score over 0.18 had a MST of 187 days, whilst MST was not reached (at 
3668 days) in dogs with a lower score.    
1.2.2.8. Intratumoural microvessel density 
The vascularisation of a tumour is imperative for tumour growth and metastasis 
(Weidner, 1995). The number of microvessels per square millimetre was found to 
be an independent prognostic factor along with mitotic count in 32 dogs with 
MCTs (Preziosi, Sarli and Paltrinieri, 2004).  
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1.2.2.9. Serotonin 
Serotonin (5-HT) is a vasoactive substance which has very wide spectrum of 
actions, including promoting cellular proliferation, differentiation, maturation 
and migration (Fröberg et al ., 2009). MCTs with high biological activity (grade III 
on the Patnaik grading system), express less serotonin and also less 5-HT1AR 
(one of its receptors). This is consistent with findings in human neoplasms where 
its increased expression can indicate a favourable prognosis (Granberg et al ., 
2000). Correlation to prognostic information was not examined in dogs. 
1.2.2.10. Tumour suppressor in lung cancer-1 
Tumour suppressor in lung cancer-1 (TSLC-1) is a tumour suppressor gene which 
inversely correlates with MCT Patnaik grade (Taylor et al ., 2010). TSLC-1 
expression also strongly linked to the behaviour of Grade II MCTs in a cohort of 
dogs used previously for Ki67 staining (Maglennon et al . 2008). Despite this, 
results did not reach significance and this can therefore not be reliably used as a 
prognostic factor without further investigation. 
1.2.2.11. DNA methylation status 
The epigenetic modification of cells can result in or facilitate the progress of 
cancer by influencing gene expression (Hanahan and Weinberg, 2011). DNA 
methylation is the addition of a methyl group to a cytosine base that precedes a 
guanine base. Hypomethylation results in gene expression and hypermethylation 
results in gene suppression. When these occur on oncogenes and tumour 
suppressor genes respectively, tumour progression can result. Given the 
availability and successful application of treatments which can modify 
methylation in human haematopoietic malignancies (Curran, 2013), this may 
have therapeutic as well as prognostic implications in veterinary medicine. 
Therapies targeting methylation have been used successfully with veterinary 
species in-vitro and in vivo (Hahn et al ., 2012; Flesner, Kumar and Bryan, 2014). 
There are concerns however that targeting hypermethylation of specific genes 
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can result in hypomethylation of others and thus promotion of metastasis (Szyf, 
2008). 
Global DNA hypomethylation identified by immunostaining of 5-methyl cytosine 
is more common in biologically aggressive canine MCTs than well differentiated 
tumours (Morimoto et al ., 2016). This finding warrants further investigation, 
although the therapeutic targeting of global hypomethylation is difficult to 
achieve.  
1.2.2.12. Fibroblast activating protein  
Fibroblast activating protein (FAP) is a serine protease which has roles in tumour 
initiation, progression and metastasis (Giuliano et al ., 2017). This protein is 
produced not by neoplastic mast cells, but by tumour associated fibroblasts and 
was identified using immunohistochemistry in the stroma of canine mast cells. A 
score was created based a semi-quantitative scoring system and this correlated 
positively with mast cells tumours of higher biological grade (both Patnaik and 
Kiupel grading systems, Ki-67 and MC) (Giuliano et al ., 2017).  
1.2.2.13. Others 
Markers which have been studied, but found not to correlate to either grade or 
prognosis include BCL-2, (Vascellari et al ., 2013), VEGF (Amorim et al ., 2010),  
p53 (Jaffe et al ., 2000), heat shock proteins 32 and 90 (Romanucci et al ., 2017) 
and tryptase (Kiupel et al ., 2004). COX-2 intensity but not immunohistochemical 
score or extension was not associated with biological behaviour (Vascellari et al 
., 2013; Gregório et al ., 2017). 
1.2.3. Summary of Prognosis 
Currently, clinicians base clinical decisions on the presence or absence of 
negative prognostic factors (most commonly histopathological grade, mitotic 
count and Ki67), staging procedures and surgical margins. Many of the pre-
histopathological factors appear unreliable, not repeatable or inaccurate over 
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multiple studies and there is inconsistency in assessment of histopathological 
markers with regard to measurement technique, adding subjectivity to their use 
as markers of biological activity.  
Identifying novel biomarkers to assist differentiation of LG and HG MCTs could 
aid prognostication and allow for more evidence-based clinical decision making 
algorithms to be produced. Serum biomarkers are an attractive prospect in this 
setting as blood sampling is often indicated for staging or health profiling of dogs 
with cancer and avoids the potential of complications associated with biopsy. 
1.3 Biomarkers 
A biomarker is defined as ‘a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention’ (Biomarkers 
Definitions Working Group. 2001). Identification of biomarkers can allow 
targeted therapy, detection of early stage disease, relapse and remission, 
assessment of the effectiveness of therapy and the prognosis of disease (Pang & 
Argyle 2010). In veterinary oncology, proteins, especially acute phase proteins, 
haematological parameters and also tissue biomarkers have been investigated as 
biomarkers. All of these may have potential as prognostic biomarkers for MCTs.  
Some serum biomarkers have been explored with respect to MCTs, although 
there is no information on their prognostic significance or ability to predict 
biological behaviour (Chase et al ., 2012). Considering that mast cells within 
MCTs often release their vasoactive granules leading to systemic clinical signs; 
there is a reasonable probability that MCTs will affect concentrations of serum 
proteins that could be identified as biomarkers and that these could improve the 
clinician’s ability to treat disease appropriately. 
1.3.1. Serum Protein Biomarkers 
Proteins serve a number of functions in both health and disease states, with the 
same protein often performing numerous functions. In broad terms, proteins can 
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be responsible for structure and organisation of cells, involved in cell signalling, 
membrane transport, catalytic reactions or involved in reaction coupling. 
Protein is not stored within the body and therefore concentrations are 
continually regulated and fluctuant, varying markedly in disease states 
(Engelking 2014). 
A number of techniques are available to evaluate known serum proteins. The 
concentration of individual proteins or larger groups can be determined using 
spectrophotometry and this is routinely performed as part of a biochemical 
profile (Engelking 2014). Immunoturbimetric methods and ELISA can also be used 
to measure the concentrations of specific serum proteins, with varying accuracy, 
sensitivity, specificity, cost and availability (Ceron, Eckersall and Martýnez-
Subiela, 2005). The lack of standard samples and quality control schemes are 
currently limiting more widespread, routine use of many of these methods to 
measure specific protein concentrations (Eckersall and Moreira dos Santos 
Schmidt, 2014).  
The large-scale evaluation of proteins expressed in a tissue or organism at any 
moment in time is known as proteomics and this may involve the measurement 
of a known protein or an attempt to identify the entire proteome. In order to 
evaluate the entire proteome in serum and identify novel protein biomarkers, 
the serum must first be separated into protein fractions, which can then be 
further analysed by mass spectrometry (MS) to identify and also quantify the 
proteins present. 
A problem recognised in identifying serum protein biomarkers stems from 
difficulty in distinguishing proteins which have leaked into the circulation from 
tumour cells and those which are blood proteins. Fewer than 1% of discovered 
cancer biomarkers reach clinical use and this is due in part to commonplace 
‘false discoveries’, non-specific biomarkers and differences in the proteome 
between sexes and in animals of differing age (Kycko and Reichert, 2014).  
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1.3.2. Quantification of known serum proteins 
1.3.2.1. Albumin Globulin Ratio 
Albumin is produced solely in the liver and has numerous roles, including 
maintaining plasma oncotic pressure. It is the most abundant serum protein in 
the dog, representing 35-50% of the total protein concentration in health. 
Hypoalbuminemia may result from hepatobiliary dysfunction, but can also be a 
response to other disease- a negative acute phase response. Albumin 
concentration is typically measured using spectrophotometric methods such as a 
bromcresol green dye-binding method (Ceron, Eckersall and Martýnez-Subiela, 
2005). 
Globulins account for the majority of plasma proteins other than albumin and 
varying concentrations of any combination of hundreds of globulins comprise the 
globulin fraction of serum. The globulin concentration in dogs is typically 
calculated by subtracting the albumin concentration from the total solids 
(typically also measured spectrophotometrically).  
The albumin to globulin ratio (AGR) has been used as a prognostic biomarker in 
human neoplasia. The AGR reflects a negative acute phase response (reduction 
in albumin concentration) seen in many neoplastic conditions alongside an 
increased globulin concentration (Stockham and Scott, 2008). Albumin is reduced 
by its consumption and albumin production is inhibited by chemokines; the 
concentrations of numerous globulins rise as a result of an inflammatory state- 
part of the acute phase response (Azab et al ., 2013). The combination of these 
factors into a ratio ameliorates confounding factors present when measuring 
only one or the other - such as dehydration falsely increasing the serum albumin 
value (Azab et al ., 2013). The AGR has proved to be prognostic for human 
colorectal cancer, irrespective of whether serum albumin is within the normal 
reference range (Azab et al ., 2013). AGR has been examined in veterinary 
conditions such as leishmaniasis and feline infectious peritonitis and is a useful 
monitoring and diagnostic biomarker in these conditions (Amusategui, Sainz and 
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Tesouro, 1998; Hartmann et al ., 2003). AGR was found to be useful at 
predicting whether a soft tissue mass was either a soft tissue sarcoma or benign 
soft tissue mass, with an AGR of less than 1·033 giving a sensitivity of 86·4% and 
a specificity of 53·8% for identifying soft tissue sarcomas. AGR was not useful at 
predicting the grade of soft tissue sarcoma in the same population (Macfarlane 
et al ., 2015). 
1.3.2.2. Acute Phase Proteins 
Acute phase proteins (APPs) are circulating proteins in which trauma, 
inflammation or infection result in a concentration change of a magnitude of 
greater than 25% (Eckersall and Bell, 2010). The function of this response is to 
promote recovery and survival of the organism in the acute setting in response 
to stressors. The acute phase response is initiated and propagated by monocytes 
and macrophages, although mast cell degranulation may also play a role. 
Numerous cytokines mediate this process and can result in transcription of APPs 
within the liver. These cytokines include transforming growth factor beta, 
interleukin-1 and interleukin-6 and tumour necrosis factor (Baumann and 
Gauldie, 1994). Measured concentrations of APPs are sensitive in detecting 
inflammation, but lack specificity (Eckersall and Bell, 2010).  
Numerous APPs have been examined as biomarkers in veterinary medicine, in 
various conditions, including neoplasia (Eckersall and Bell, 2010). Dogs with 
haematological neoplasia had increased concentrations of haptoglobin and C-
reactive protein compared to healthy controls or normal reference ranges 
(Tecles et al ., 2005; Atherton, 2013a). Dogs with MCTs have alterations in 
known APP concentrations, without significant changes in total protein 
concentration (Chase et al., 2012). C-reactive protein and α-1 acid glycoprotein 
were increased. Not all known APPs are increased in dogs with MCT however and 
haptoglobin concentration was not found to be significantly higher than 
reference value. Additionally, concentration of serum amyloid A was 
unexpectedly lower than reference value.  No difference was identified in acute 
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phase concentrations between different grades of MCT, when considering the 
three tiered Patnaik grading system (Chase et al ., 2012).  
1.3.3. Exploration of the Proteome 
1.3.3.1. Mass Spectrometry 
MS is a technique employed to measure the mass to charge ratio of biological 
molecules with the aim of determining their molecular weight as accurately as 
possible (Koomen, Hawke and Kobayashi, 2005). With regard to proteins, the 
mass spectrometer identifies the amino acid sequences then proteins are 
identified based on probabilities when the amino acid sequences are matched to 
a known database.  
The usefulness of MS as a technique results from its sensitivity, being able to 
analyse peptides with concentrations as low as 10-18 molar (Martin et al ., 2000). 
The downside to this sensitivity is that larger samples may overwhelm the 
capabilities of this device, necessitating prior fractionation and the correct 
processing of the sample (Gerou-Ferriani, Mcbrearty, et al., 2011). 
A mass spectrometer contains a means of ionising the substance to be analysed, 
a mass analyser which measures the mass to charge ratio of the analyte which 
has been ionised and a detector that measures the number of ions present at 
each value (Aebersold and Mann, 2003).  
Electrospray ionisation and matrix assisted laser desorption/ionisation (MALDI) 
are the techniques generally used to ionise solutions and solids respectively 
(Aebersold and Mann, 2003). Nanoelectrospray rather than electrospray 
ionisation is now frequently used to create a narrower diameter spray of ions, 
which improves sensitivity, robustness and reduces the volume of sample 
required (Gibson, Mugo and Oleschuk, 2009). After ionisation, the particles are 
analysed by one or more of four classes of mass analysers: quadrupole ion trap; 
linear ion trap; time of flight and Fourier-transform ion cyclotron resonance 
(Han, Aslanian and Yates, 2008). All have various strengths and weaknesses and 
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can also be used in tandem configurations (Lippolis and Reinhardt, 2011).  The 
ion detector can also come in many forms but is typically an electron multiplier 
which can turn a signal from a single ion into a much larger electrical current 
(Lippolis and Reinhardt, 2011). Tandem MS (frequently shortened to MS/MS) 
involves the further fragmentation of detected ions into smaller peptides by 
collision with an inert gas with further separation by mass (Hunt et al ., 1986). 
This allows better sensitivity for detecting small concentrations of proteins (De 
Hoffmann, 1996).  
Mass spectrometers analyse either entire proteins or enzymatically produced 
peptides, from which, after fractionation, the entire protein structure is 
elucidated. Typically enzymatic digestion is performed subsequent to protein 
fractionation and this sort-then-break approach was first described using two 
dimensional electrophoresis fractionation (Henzel et al ., 1993). Analysis of 
entire proteins is often limited by the requirement to separate a mixture of 
proteins into single or simple mixtures and by the inability to analyse large 
entire proteins due their tertiary structure (Han, Aslanian and Yates, 2008).  
Subsequent to the detection of the mass to charge value of a peptide or protein, 
a protein or gene database is often searched in order to identify the protein 
(Han, Aslanian and Yates, 2008). Examples include the MASCOT database, which 
combines three types of searching and produces a score to allow the significance 
of a result to be assessed (Perkins et al ., 1999). In the dog, the identification of 
proteins has been facilitated by the sequencing of the genome, which means 
that proteins can be predicted from their amino acid sequence if required 
(Atherton et al . 2013a). 
Mass spectrometers have a role in veterinary proteomics in assisting the 
identification of potential biomarkers or toxins. Unlike a genome which is 
generally identical in all cell types, the proteome changes in response to stimuli 
and can markedly vary from cell to cell and tissue to tissue independent of 
genomic changes (Han, Aslanian and Yates, 2008). Interrogation of the 
proteome, therefore allows identification of epigenetic changes and their 
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consequences which would not be identified using only genomic techniques.  
Epigenetic changes are widely established as a factor in the development and 
progression of cancer (Feinberg, Ohlsson and Henikoff, 2006).  
MS has previously been used to search for biomarkers of canine cancer (Kycko 
and Reichert, 2014). Subsequent to exosome segregation, MS was used to 
identify exosome proteins, which could be used to differentiate dogs with 
osteosarcoma from control dogs, as well as predicting the stage of the dog’s 
treatment (Brady, 2018). Numerous other studies have utilised MS after other 
forms of fractionation. These are documented in the following sections of this 
thesis examining methods of protein fractionation.  
1.3.3.2. Serum Protein Electrophoresis 
Electrophoresis is a technique employed to separate biological substances using 
an electric field provided by immersed electrodes and a matrix on which the 
substances can migrate, typically a polyacrylamide gel for protein separation. 
One dimensional polyacrylamide gel electrophoresis permits analysis of the size, 
concentration, isoelectric point and purity of proteins (Shi and Jackowski, 1998). 
After separation, the gel is stained and densitometric analysis is performed to 
calculate the relative concentrations within known protein bands. From 
knowledge of the total protein concentration, the  absolute concentrations of 
protein within each band can then be calculated (Abate et al ., 2000).  
After electrophoresis six bands of serum proteins are clearly identifiable and 
these include albumin and five types of globulins- α1,α2,β1,β2 and γ (Ceciliani 
et al ., 2013). A large scale one-dimensional serum protein electrophoresis (1D-
SPE) study of 147 dogs established a reference range for canine serum proteins 
of 75 healthy control samples (Tappin et al . 2011). Despite this, it was 
suggested that each laboratory should establish their own reference intervals 
due to differing methodologies between centres.  
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Proteins in each globulin fraction or band may be up- or down-regulated by 
disease processes. 1D-SPE is most commonly used as a diagnostic tool in dogs to 
evaluate hyperglobulinaemia. A monoclonal gammopathy representing a 
markedly increased production of a single immunoglobulin by B cells is identified 
as a sharp peak on densitometric analysis. In a population of 147 dogs, in which 
1D-SPE was performed mostly due to hyperglobulinaemia, eight had a 
monoclonal gammopathy attributable to lymphoid neoplasia (Tappin et al ., 
2011). In another population of eighteen dogs with monoclonal gammopathy, 
taken from over 3,900 serum protein electrophoresis results, thirteen had 
lymphoid neoplasia and five had infectious disease which may be present in 
certain inflammatory and neoplastic conditions (Giraudel, Pagès and Guelfi, 
2002).  
1.3.3.3. Two Dimensional Electrophoresis 
Whereas one dimensional serum electrophoresis can fractionate the serum 
proteome into six identifiable fractions, it generally does not provide adequate 
separation to allow MS analysis to identify individual proteins. An example of 
this was shown when the serum proteome of cats with lymphoma was been 
evaluated, using 1D-SPE as a sorting mechanism prior to MS (Gerou-Ferriani et al 
. 2011). The separation achieved did not result in sufficient protein separation 
for clear identification of individual proteins. 
Therefore, gels which can separate proteins in two dimensions, allowing 
resolution of up to 5000 protein representing spots on one gel are frequently 
used (Magdeldin et al ., 2014). 
1.3.3.3.1. Two dimensional polyacrylamide gel electrophoresis 
One of the most commonly used methods of two dimensional serum protein 
electrophoresis (2D-SPE) is two dimensional polyacrylamide gel electrophoresis 
(2D-PAGE). The first dimension of separation typically involves one of three 
methods of finding the isoelectric point and separating by pH. The second 
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dimension is typically separation by molecular weight (Magdeldin et al ., 2014). 
This technique is considered robust and provides adequate separation to allow 
mass spectrometric analysis, but has a low reproducibility; a poor ability to 
detect low concentrations of proteins (especially if other proteins are present at 
very high concentrations); is low output and labour intensive (Magdeldin et al ., 
2014). 
Numerous studies have scrutinised the canine serum proteome using 2D-PAGE 
prior to MS. In obese dogs, three proteins were expressed differently in the 
serum than that of dogs with a normal weight (Tvarijonaviciute et al . 2012). 
The sera were evaluated using 2D-PAGE, before identifying the proteins by 
MALDI time of flight MS (MALDI-TOF MS). Serum retinol protein four and clusterin 
precursor were both up-regulated and α1-antitrypsin was down-regulated. 
Changes in steroid hormones during the pre-ovulatory period of dogs have also 
been examined using 2D-SPE (Fahiminiya et al . 2010). 2D-SPE followed by 
MALDI-TOF MS showed that neuron specific enolase was higher in dogs with 
meningoencephalitis of unknown aetiology (Nakamura et al . 2012). When 
considering cancer, 2D-SPE followed by MS identified basic transcription factor-3 
as being increased in dogs with lymphoma (Kycko et al ., 2018). Four 
autoantibodies, with potential application as biomarkers in both canine and 
human tumours were identified using a combination of 2D-PAGE and MS on the 
serum of dogs with mammary neoplasms (Zamani-Ahmadmahmudi, Nassiri and 
Rahbarghazi, 2014).  
A variety of different bodily fluids and tissues have also been assessed in an 
attempt to discover potential protein biomarkers for dogs with cancer. Analysis 
of tears by 2D-PAGE and MALDI MS from dogs with a variety of neoplasms showed 
albumin and actin were reduced and a protein thought to be analogous to human 
lacryglobulin was increased (de Freitas Campos et al ., 2008). Canine mammary 
tumour tissue has been analysed using the combination of fractionation and 
identification of proteins. These analyses identified a difference in the protein 
expression of metastatic and non-metastatic tumours and when different stages 
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of malignant progression were compared. (Klopfleisch et al ., 2010; Klose et al ., 
2011). Comparison of lymph node tissue from dogs with B-cell lymphoma, when 
compared to a control population identified both up- (macrophage capping 
protein) and down-regulated proteins (prolidase, triosephosphate isomerase, and 
glutathione S-transferase) with potential utility as biomarkers (McCaw et al ., 
2007). 
1.3.3.3.2. Two- Dimensional Difference Gel Electrophoresis  
Two-dimensional difference gel electrophoresis (2D-DIGE) utilises the same 
principles as 2-dimensional electrophoresis in that the samples are separated in 
two dimensions. This technique minimises gel to gel variation by running more 
than one sample on the same gel with each sample being labelled by a separate 
dye. This allows differential expression of proteins to be identified, however 
identification of the protein in question still requires excision of a protein spot 
and MS (Matharoo-Ball et al ., 2008). MALDI-TOF was used following 2-
dimensional difference gel electrophoresis to identify differences in the 
proteome of healthy dogs to those with a transected anterior cruciate ligament 
(Gharbi et al .2013). Fetuin B and complement C3 were increased in diseased 
dogs and hyaluronan binding protein 2, inter-α-trypsin inhibitor H4, complement 
C1s and C4 were reduced.  
Using 2D-DIGE, collagen XXVII peptide was increased in the serum of dogs with 
haemangiosarcoma. Collagen XXVII peptide also reduced after splenectomy and 
increased upon recurrence of the disease in two dogs (Kirby et al ., 2011). 
Proteomic expression profiling of canine osteosarcoma cells was performed using 
a combination of 2D-DIGE and MS to identify overexpression of MiR9 (Fenger et 
al ., 2016). When 2D-DIGE and MALDI-TOF MS were used to compare canine 
prostatic tumours to normal urothelium three overexpressed proteins, GRP78, 
GRP74 and keratin-7 were identified (LeRoy et al ., 2004). 
The combination of 2D-DIGE and MS on tumour tissue identified a number of 
proteins which may be involved in the aetiology, pathogenesis or crucially the 
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biological behaviour of MCT (Schlieben et al . 2012). With MCT classified 
according to the two-tiered grading system, 13 proteins with significant 
differential expression were found. These proteins were grouped according to 
function and within groups of function, some proteins were up regulated while 
others were down regulated in HG MCT. Transferrin was down-regulated and 
stress response proteins such as HSPA9, PDIA3, TCP1A and TCP1E were up-
regulated in HG MCT. Cell motility and metastatic proteins ANXA6, ACTR3 and 
WDR1 were also increased in HG MCT and the expression of two other proteins, 
ANXA2 and ACTB were decreased. When the differentially expressed proteins 
were further analysed, it was concluded that HG MCT have a higher resistance to 
cellular stress. HSPA9 has been identified as a therapeutic target as HSPA9 
inhibitors are available as a therapeutic for human neoplasia.  
1.3.3.3.3. One dimensional serum electrophoresis followed by 
polyacrylamide gel electrophoresis.  
A novel technique employing 1D-SPE, followed by a 2D-PAGE and MS was used to 
evaluate the canine serum proteome (Atherton et al . 2013a). Individual protein 
bands were then excised from the gels and MS was used in combination with 
canine gene sequencing data to identify proteins. This did not require isoelectric 
focusing in the two-dimensional phase, which is technically demanding. The 
results were an improvement on previous work to characterise the serum 
proteome by Abate et al., (2000) as the high resolution electrophoresis used 
previously was dependent on possessing antibodies to the proteins, meaning that 
only characterisation of known proteins could occur (Atherton et al . 2013a).  
Thirty-two proteins were identified from the serum of two healthy dogs and as 
the proteins were identified in their specific globulin fraction, it was proposed 
that changes within the fraction on the 1D-SPE could possibly be used to identify 
diseased dogs. By comparing these results from the population of healthy dogs to 
that of three dogs with HG multicentric lymphoma (Atherton et al . 2013b), 10 
proteins were identified that were not found in the normal samples. These 
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included clusterin and many established acute phase proteins, α2 macroglobulin, 
inter-α-trypsin inhibitor, α anti-chymotrypsin and haptoglobin. Albumin levels 
were significantly reduced as was kininogen, possibly due to consumption as part 
of a pro-inflammatory process. 
1.3.4. Neutrophil to lymphocyte ratio 
As well as using serum proteins as biomarkers, circulating inflammatory cells 
have also been studied. The link between cancer and inflammation has long 
been established, but has received growing attention in recent years. Cancer 
promoting inflammation was added as an ‘enabling characteristic’ to the revised 
Hallmarks of Cancer (Hanahan and Weinberg, 2011). Inflammation may both play 
a role in the aetiology of cancer including canine MCTs (Govier, 2003) and be a 
consequence of it (Sideras and Kwekkeboom, 2014). Neutrophils are involved in 
angiogenesis and as tumour promoting inflammatory cells (Hanahan and 
Weinberg, 2011). Conversely, the tumour microenvironment may also be 
infiltrated by immunosuppressive cells such as T-regulator cells (Wang and Ke, 
2011), other T and B lymphocytes, as well as neutrophils which can assume 
immunosuppressive properties (Hanahan and Weinberg, 2011). As a result of this 
immunosuppressive infiltration, cytotoxic lymphocyte numbers were reduced in 
comparison to normal populations in a study of a broad range of canine 
neoplasms (not including MCT) (Itoh et al ., 2009).   
Taking advantage of these characteristics, the neutrophil to lymphocyte ratio 
(NLR) has been examined as a prognostic tool in many human cancers including 
haematological neoplasms (Sideras and Kwekkeboom, 2014). Over 60 studies in 
over 37,000 patients with various neoplasms were reported in a review, with a 
number of new studies since published and a further review highlighting the 
utility of the biomarker in breast cancer (Guthrie et al ., 2013; Ethier et al ., 
2017).  
Complete blood counts are recommended in the evaluation of MCTs which are in 
a location not amenable to surgery or if there is evidence of negative prognostic 
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factors (Welle et al ., 2008), Therefore use of this ratio as a biomarker would 
involve no further investigation for the dog or cost to its owner. A disadvantage 
of this ratio however is that both cell types can be influenced by a very wide 
range of unrelated processes (Sideras and Kwekkeboom, 2014) such as 
immunosuppressive and anti-inflammatory drugs and concurrent infections. The 
presence or absence of immune cells in the tumour micro-environment may also 
bear no relation to numbers within a peripheral sample (Sideras and 
Kwekkeboom, 2014). 
To date and not including the published material from this thesis, there have 
been at least five studies examining the utility of the NLR in veterinary oncology  
(Macfarlane et al ., 2015; Mutz et al . 2015; Skor et al ., 2017; Davies et al ., 
2018; Fernandez and Chon, 2018). NLR was not identified as a significant 
prognostic variable in canine multicentric lymphoma (Mutz et al ., 2015). 
However, this is a diverse disease and this cohort was treated in a number of 
ways. It was suggested that further prospective evaluation of this biomarker may 
prove useful (Mutz et al ., 2015). Another ratio of haematological cells is 
prognostic for canine B-cell lymphoma, when treatment was standardised: the 
lymphocyte to monocyte ratio (Marconato et al ., 2015).  
The NLR can be used to predict whether a soft tissue mass is a soft tissue 
sarcoma or benign soft tissue tumour. Above a threshold of 4.519, there is a high 
sensitivity of 95.5% and a specificity of 57.5% for identifying soft tissue sarcoma. 
Pre-treatment NLR may therefore allow for better treatment planning. NLR was 
not able to predict grade of soft tissue sarcomas in the same population 
(Macfarlane et al ., 2015). 
On univariable analysis, NLR was found to be a significant prognostic variable for 
dogs with MCT with a variety of grades, treated with a variety of different 
modalities (Skor et al ., 2017). However, it was not an independent prognostic 
factor on multivariate analysis. NLR was a more useful tool than either of its 
constitutive parts (the absolute neutrophil and lymphocyte concentrations).  
However, retrospective analysis meant that treatment could not then be tailored 
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in response to differing NLRs. No comparison was made between NLR and grades 
of MCT to identify potential use in predicting grade and therefore to guide 
treatment decisions. The same study identified the neutrophil to eosinophil ratio 
as an independent prognostic variable, with a lower eosinophil count identifying 
shorter survival times.  
1.4 Aims of this thesis 
There are currently few objective measurements which can differentiate 
between LG and HG MCT without obtaining a sample for histology. However, 
biomarkers used in human and veterinary medicine might, if applied to MCTs, 
allow better differentiation. Identification of reliable biomarkers would allow 
more informed treatment decisions to be made and possibly help indicate the 
prognosis for each individual patient.  
The aims of this thesis were: 
1. To determine the potential use of NLR and AGR in predicting the 
biological grade of canine MCTs in dogs with gross tumour burden. 
2. To identify novel serum biomarkers by searching for differences in the 
proteome of dogs with known HG and LG MCT and by comparing dogs with 
HG and LG MCT to healthy controls. 
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2 Methods 
2.1 Case Selection 
2.1.1. Dogs with Mast Cell Tumours 
To assess suitability for inclusion, an electronic patient database was searched 
to identify all dogs presented to the University of Glasgow Small Animal Hospital 
between June 2008 and September 2015 with a definitive diagnosis of mast cell 
neoplasia. These dogs were presented for diagnosis and treatment of their 
disease as appropriate. Dogs were included into the study if they met the 
following criteria: 
• A complete blood count and/or biochemical analysis were performed at 
the University of Glasgow Small Animal Hospital, whilst the dog had a 
gross MCT. This formed part of the clinical staging process. 
• The dog was not receiving (or had received within the prior ten days) any 
medication with the potential to alter the serum proteome or numbers of 
circulating blood cells by any route of administration. This was considered 
to be any corticosteroid, anabolic steroid, phenobaritone, ketoconazole, 
any chemotherapeutic agent, any tyrosine kinase inhibitor or any other 
immunomodulatory drug (oclacitinib, ciclosporin, azathioprine, 
mycophenolate, etc.). 
• No co-morbidities were evident on clinical examination, clinical history or 
after analysis of clinical staging results which could influence either 
protein or leucocyte results. Examples include atopic dermatitis and 
protein losing enteropathy. 
• No surgical procedures had been performed in the fourteen days prior to 
time of blood sampling.  
• The diagnosis of a MCT was made histopathologically, allowing the tumour 
grade to be attained.  
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Excess blood, which was deemed surplus to requirements for haematological and 
biochemical profiling which formed part of the diagnostic investigation, was 
decanted into serum tubes (International Scientific Supplies Ltd, Bradford, UK). 
These samples were allowed to clot and then centrifuged at 7,000 rpm for three 
minutes (Minispin, Eppendorf, Hamburg, Germany). The serum was separated 
into another plain tube and stored at -80°C.  
The following clinical factors were recorded from the medical record; age, sex, 
breed, tumor grade, location and size, presence of lymph node and distant 
metastasis, albumin and globulin concentrations, absolute neutrophil and 
lymphocyte count. Further staging evaluation (abdominal and/or thoracic 
imaging) was not a pre-requisite for inclusion but any staging procedures were 
documented. With regards to tumour size, the largest single dimension was used 
for single lesions, with the sum of the largest single dimension used in multiple 
MCTs (including lymph node metastasis). The WHO stage was also recorded 
where possible. The tumour location was divided into four groups, head and 
neck, extremity, other or multiple.   
If histopathological grading was performed prior to the routine use of the two-
tier, Patnaik grading system, tumours were re-graded to the Kiupel grading 
system by a single, board certified anatomic pathologist (Timothy Scase, Bridge 
Pathology Ltd.). In multiple MCTs, if any lesions were deemed HG, the dog was 
classified in the HG group.  
2.1.2. Control Cases 
Control samples were from six healthy adult dogs which were voluntarily offered 
by their owners for use as blood donors. These dogs had no known illnesses, had 
not received any medications in the preceding fourteen days and did not have 
any significant haematological or serum biochemical abnormalities. Serum was 
separated from these samples as for the study samples and stored under the 
same conditions.  
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The samples for both control and study dogs were taken after at least a ten hour 
fast. All procedures and the use of the samples were approved by the Research 
Ethics Committee of the College of Medicine, Veterinary and Life Sciences, 
University of Glasgow.  
2.2 Neutrophil to Lymphocyte Ratio and Albumin to Globulin Ratio 
Blood samples were decanted into potassium EDTA and lithium heparin tubes 
(International Scientific Supplies Ltd.). Albumin concentration was measured 
biochromatically using a bromocresol green dye-binding method and total 
protein concentration was measured using a biuret spectrophotometric assay in 
an automated analyser (Olympus AU640, Olympus, Tokyo, Japan). Globulin 
concentration was calculated as the difference between these values. An 
automated haematology analyser (Advia 2120 with veterinary package, Siemens, 
Munich, Germany) was used for haematological analysis. Results were verified 
using a manual differential from a wedge blood smear stained using May-
Grünwald Giemsa Stain. 
2.3 Proteomics 
2.3.1. One dimensional Agarose Gel Electrophoresis 
Protein electrophoresis was performed using a one-dimensional agarose gel 
(Hydragel Protein (E) K20, Sebia, Camberley, UK). Ten microlitres of serum from 
each dog was loaded onto the gel along with an animal-based control serum 
(Pathonorm H, Sero AS, Oslo, Norway). The loaded gel was then placed into a 
buffering solution of 0.092% W/V barbital, 0.515% W/V sodium barbital and 
0.01% sodium azide solution (Tris-Barbital Buffer, Sebia) and electrophoresed for 
twenty minutes at a constant voltage of 100 mV. The gel was then fixed in acid 
alcohol for fifteen minutes before being dried at 37°C for at least sixteen hours. 
A stain (Amido Black, Sebia) was then applied for four minutes, and the gel was 
destained for a further four minutes (Destaining Solution, Sebia). 
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A digitally captured (UMAX PowerLock III flatbed scanner, UMAX UK Ltd, Milton 
Keynes, UK) colour image of this one dimensional gel was then used to perform 
densitometric analysis (ImageJ, National Institutes of Health, Bethesda, 
Maryland, USA) to quantify the percentage of the total protein present in each 
of six protein fractions, albumin, α-1, α -2, β-1, β-2 and γ. 
The results were reviewed to establish a boundary of each fraction. The absolute 
values for each protein fraction were then calculated using the total protein 
result obtained previously from the same blood sample by the biuret method. 
Six dogs (three with LG MCTs and three with HG MCTs) were then selected as 
clinically representative of their respective tumour grade along with three 
controls. 1D-SPE was repeated on these dogs as the first stage of a two 
dimensional electrophoresis. A further 10 µl of serum was loaded into lanes one 
and three to seven and the gel was then electrophoresed and dried as described 
above. Lane one was then excised from the remainder of the gel and stained as 
described above. The six protein fractions were identified on this stained lane 
and it was then used as a guide to dissect the protein fractions from unstained 
lanes three to seven. The samples from lane three to seven were combined to 
ensure an adequate mass of protein was available with which to perform 2D-
PAGE electrophoresis.  
2.3.2. Polyacrylamide Gel Electrophoresis 
The excised protein fractions from the 1D-SPE were then processed to extract 
the protein from the gel. Individual protein fractions were sectioned into small 
fragments and placed into a 0.5 ml Eppendorf tube (Fisher Scientific, 
Loughborough, UK). A buffer containing 43 µl of Laemmli sample buffer (Biorad), 
43 µl of deionised water and 4.5 µl mercaptoethanol (Sigma, Dermstadt, 
Germany) was added to the tube which was heated to 95°C for five minutes, 
then cooled and stored for 12 hours, before being heated to 95°C for a further 
five minutes. Ten microlitres of extracted protein was then used for 2D-PAGE 
(Criterion TGX Precast Gel, Bio-Rad, Hercules, California), with one lane used 
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for a protein ladder (Page Ruler Pre Stained Protein Ladder, Thermo Scientific, 
Waltham, USA) to facilitate comparison between gels.  
The gels were electrophoresed at 300 V for fifteen minutes in a running buffer 
(Bio-Rad XT MOPS Running Buffer, BioRad Inc). Gels then were stained using a 
Coomassie Blue stain (Biosafe Coomassie Blue, BioRad Inc) for one hour with the 
gel placed on a rocking device. The gel was then rinsed in an acid alcohol 
solution (20% methanol and 7.5% acetic acid) prior to destaining for twelve hours 
in acid alcohol with rocking. The gel then was placed in distilled water for 24-48 
hours. 
Digital images of the polyacrylamide gels were then captured using a flatbed 
scanner (UMAX PowerLock III flatbed scanner) and protein bands within each 
lane were identified. Each identified band was then carefully excised from the 
gel. This was performed within a laminar flow hood using instruments which 
were rinsed in ethanol and distilled water after each band was excised. Each 
individual band was placed into a 0.5 ml Eppendorf tube and stored until 
required at -80°C.  
2.3.3. Mass Spectrometry 
Prior to MS, the protein within the gel pieces was digested using trypsin. Larger 
pieces were cut into smaller fragments and were washed in 500 µl of 100 mM 
ammonium bicarbonate (GE healthcare, Chicago, Illinois) for thirty minutes on a 
shaker. Gel pieces were then washed in 500 µl of 50% acetonitrile/100 mM 
ammonium bicarbonate (GE Heathcare) for thirty minutes with shaking. This 
second wash was then repeated. Fifty microlitres of acetonitrile was then added 
to shrink gel pieces for 10 minutes. The solvent was then removed and gel pieces 
were completely dried in a vacuum centrifuge. A sufficient amount of 20mg/ml 
of trypsin (Promega sequencing grade trypsin, Promega Ltd.) suspended in 25mM 
ammonium bicarbonate was then used to resuspend the pieces, which were then 
left for at least 12 hours at 37˚C. Gel pieces were then pelleted and all liquid 
transferred to a ninety six well microplate (Thermo Scientific). Twenty 
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microlitres of 5% formic acid was added to the remaining gel piece and this was 
incubated for twenty minutes on a shaker. Forty microlitres of acetonitrile was 
then added to this, before a further twenty minutes of shaking. The gel was 
pelleted once more and the solution pooled with the previously removed 
solution in the ninety six well microplate. Samples were dried in a vacuum 
microcentrifuge and stored at -80˚C until MS was performed. All the above steps 
were performed in a laminar flow hood. 
For mass spectrometric analysis, stored tryptic peptides were solubilized in 0.1% 
formic acid and fractionated on a nanoflow Ultimate 3000 uHPLC system 
(Thermo Scientific) before being analysed by nanoelectrospray ionisation 
CaptiveSpray MS on an Amazon Speed ion trap MS/MS (Bruker Daltonics, 
Billerica, USA). Peptide separation was performed on a Pepmap100 C18 reversed 
phase column (Thermo Scientific), using a 4 - 40% v/v gradient (in 0.1% v/v 
formic acid, 80% acetonitrile) run over 23 min at a flow rate of 0.3 ml / min. 
This was followed by an increased gradient of 40-100 % v/v over 9 minutes. The 
column was washed for a further 5 minutes before returning to starting 
conditions. Next, a continuous duty cycle of survey MS scan was performed 
followed by up to ten tandem MS analyses of the most abundant peptides. These 
were selected using the most intense multiply charged ions with dynamic 
exclusion for 12 seconds. 
MS data were processed using data analysis software (Bruker Daltonics) and the 
automated Matrix Science Mascot Daemon server (v2.5.0). Protein identifications 
were assigned using the Mascot search engine to interrogate Caniformia protein 
sequences in the National Centre for Biotechnology Information database (04 
April 2015), allowing a mass tolerance of 0.4 Da for both MS and MS/MS analyses. 
Oxidation of methionine was considered and carbamidomethylation of cysteines 
was assumed. Mascot Molecular Weight Search (MOWSE) scores of 64 or greater 
indicated identity or extensive homology (p<0.005). When proteins matched 
sequences from multiple species, only the species with the highest Mascot 
Molecular Weight Search score was included in the results unless a match with a 
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MOWSE score of over 64 within the species Canine lupus familiaris was detected 
and this was then included in preference. 
 
2.4 Statistical Analyses  
2.4.1. Neutrophil to Lymphocyte Ratio and Albumin to Globulin Ratio 
All statistical analyses were performed using statistical software (IBM SPSS 
Statistics for Windows 22 & Minitab 16). Due to the number of cases and after 
visual inspection of Q-Q plots for independent variables, non-parametric analysis 
was used and data are presented as medians and ranges. Mann-Whitney U Tests 
were used to compare haematological and biochemical parameters, NLR and 
AGR between high and LG MCTs. Univariable and multivariable logistic regression 
analyses were used to evaluate the association of clinical factors and measured 
parameters to the MCT grade (high or low); factors with p<0.2 in the univariable 
model were considered for inclusion in the multivariable analysis. This was 
assembled as a manual stepwise forward logistic regression with p<0.05 
considered significant. Goodness of fit was assessed using Hosmer-Lemeshow 
goodness of fit test. Listwise deletion was used for handling missing data. ROC 
curves were constructed in order to calculate the sensitivity and specificity of 
potential biomarkers for predicting histopathological grade.  
2.4.2. One dimensional serum protein electrophoresis 
All statistical analyses were performed using statistical software (IBM SPSS 
Statistics for Windows 22 & Minitab 16). Due to the number of cases and after 
visual inspection of Q-Q plots for independent variables, non-parametric analysis 
was used and data are presented as medians and ranges. Mann-Whitney U Test, 
Kruskal-Wallis and Fischer’s exact tests were used where appropriate to compare 
protein concentrations between HG and LG MCTs and control groups.
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3 Results 
3.1 Use of the Neutrophil to Lymphocyte and Albumin to Globulin 
Ratios for Predicting Histopathological Grade of Canine Mast Cell 
Tumours 
3.1.1. Introduction 
The first aim of the thesis was to determine whether NLR and AGR were useful 
blood biomarkers for dogs bearing gross MCTs in terms of predicting tumour 
grade and outcome. Both NLR and AGR have been identified as biomarkers of 
interest in human neoplasia  (Guthrie et al ., 2013; Aksoy et al ., 2016) and may 
therefore have utility in management of MCT. This could be in directing initial 
investigation, such as whether to perform full staging examination and also in 
guiding treatment decisions. MCT which are predicted to follow a rapidly 
progressive disease course are recommended to have different initial 
investigation and treatment (Blackwood et al ., 2012) and there is therefore a 
need for an objective, cost effective, minimally invasive, reliable and accurate 
parameter which can predict the biological behaviour of cutaneous mast cell 
tumours.  In this chapter, NLR and AGR were compared between HG and LG MCT 
in a population of 61 dogs with naturally occurring MCT (62 tumours), using the 
complete blood count and biochemical results.  
3.1.2. Neutrophil to Lymphocyte and Albumin to Globulin Ratios  
Results presented in this section have previously been published elsewhere 
(MacFarlane et al ., 2016). 
Sixty one dogs met the inclusion criteria outlined in the methods section 2.1 
(Appendix 1). A male entire boxer had two LG MCTs, in different locations, 
temporally spaced by 4 years and was therefore included twice, so 62 sets of 
results were available: 14 (23%) HG and 48 (77%) LG MCTs.  
61 
 
 
 
Nineteen Labrador retrievers were included in the analyses (12 HG MCT, 7 LG 
MCT); 13 boxers all with LG MCT; 10 crossbred dogs, six of which had LG MCT; 
six golden retrievers all with LG MCT; three Staffordshire bull terriers (2 LG MCT, 
1 HG MCT); two springer spaniels with LG MCT; there were one West Highland 
white terrier, beagle, miniature schnauzer, Border collie, Anatolian shepherd, 
Pyrenean mountain dog and vizsla with LG MCT and one Jack Russell terrier and 
Lhasa apso with HG MCT.  
Thirteen male entire (9 LG MCT, 4 HG MCT), 23 male neutered (17 LG MCT, 6 HG 
MCT), six female entire (5 LG MCT, 1 HG MCT) and 20 female neutered dogs (17 
LG MCT, three HG MCT) met inclusion criteria. 
The median age for all dogs was seven years (range 1-14); for the LG group seven 
years (range 1-12) and the HG group 9.5 years (range 5-14). The distribution of 
ages in these groups is statistically significant (p=0.004). 
Of the LG MCT: 21 were located on the extremities; 14 were located on the head 
or neck; eight dogs had multiple LG MCT and five had tumours in other locations. 
Of the HG tumours: four each were present on the extremities and on the head 
or neck; one dog had multiple MCT, of which one was HG and five had MCT in 
other locations.  
Three LG MCT cases did not have available longest dimension data and this was 
therefore available for 59 cases. Overall, the median MCT size was 25mm. The 
median size of the LG MCT group was 21mm with a range 6-80mm and there was 
a median of 36mm and range of 12-140mm for HG MCT. There is a significant 
difference in tumour size between groups (p=0.026). 
No major systemic effects of the MCT were reported in either group. Four dogs 
from the LG MCT (8%) and HG MCT groups (29%) had local clinical signs. These 
local signs were: pruritus in three cases, erythema of the lesion in two cases, 
ulceration of the MCT in two cases or local oedema and swelling in one case.  
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Six dogs with LG MCT had palpably enlarged local lymph nodes. Five of these 
were confirmed as metastatic histologically and one was classed as free of 
metastasis after cytological examination. Thirteen LG cases had palpably normal 
lymph nodes, one was found to be metastatic histopathologically, six were found 
to be non-metastatic by cytological exam and two by histopathological exam. 
Seven dogs in the HG MCT group were reported as having enlarged lymph nodes. 
Three were confirmed as metastatic histopathologically and three were 
confirmed cytologically.  One HG MCT with an enlarged local lymph node was 
not found to have any mast cells on cytological examination of the lymph nodes. 
Four local lymph nodes in the HG group were reported as normal sized and not 
examined. The size of the local lymph node was not recorded for 28 LG MCTs 
and three HG MCT and cytology nor histopathology were performed. Therefore, 
in six each of the HG and LG MCT groups, there was evidence of lymph node 
metastasis.  
All MCT cases had staging including at least abdominal ultrasound and thoracic 
radiographs (two or three views) on day of blood sample collection, facilitated 
with sedation. If either the liver or spleen was considered to be significantly 
abnormal in appearance, an FNA and cytological analysis was performed. Results 
are detailed in Table 3-1. The liver was increased in size and increased in 
echogenicity in two cases each. Focal lesions and a heterogenous parenchyma 
were identified in one case each. A heterogeneous splenic parenchyma was 
identified in five cases and focal splenic lesions in two cases. There was both a 
heterogenous parenchyma and an increase in size of the spleen in a further two 
cases.  
FNA of the spleen was performed in 23 cases and hepatic FNA in nine dogs (Table 
3-1). No mast cells were seen in five of the liver samples, with occasional mast 
cells in four. In nine of the splenic samples, there were no mast cells and there 
were occasional, well differentiated mast cells in the remainder. The occasional 
mast cells were not considered to represent metastatic disease in any sample. 
There was no concerning abnormality identified on any thoracic radiograph, 
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therefore no distant metastatic disease was identified in any case at time of 
inclusion.  
 
 
 
 
Grade 
Number 
of cases 
Hepatic 
ultrasound 
abnormalities 
Hepatic 
FNA 
Metastatic 
disease 
suspected 
Splenic 
ultrasound 
abnormalities 
Splenic 
FNA 
Metastatic 
Disease 
Suspected 
Low 48 3 6 0 6 15 0 
High 14 3 3 0 3 8 0 
Total 62 6 9 0 9 23 0 
Table 3-1: Hepatic and splenic ultrasonographic abnormalities in dogs with 
gross mast cell neoplasia. FNA= fine needle aspirate 
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The majority of tumours from dogs in LG and HG groups were considered WHO 
stage I MCTs. No dogs had stage IV MCT. A full breakdown of tumour stages is 
shown in Table 3-2 and shown for each individual case in Appendix 1.
MCT Grade 
 
WHO Stage 
Low High Total 
I 34 7  41 
II 6 6 12 
III 8  1  9 
IV 0 0 0 
Total 48 14 62 
Table 3-2: World Health Organisation stage (Owen, 1980) 
distribution amongst different grades of cutaneous mast cell tumour 
being analysed for biomarker identification WHO= World Health 
Organisation, MCT= mast cell tumour.   
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Complete blood count results were available for all 62 cases. When the 
individual components of the NLR were considered, only lymphocyte 
concentration was significantly different between MCT grades, being lower in 
the HG MCT group (p=0.001). NLR was significantly higher in dogs with a HG 
MCTs (Figure 3-1) (p<0.001).  
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Figure 3-1: Box and whisker plot showing the neutrophil to lymphocyte 
ratio in grades of cutaneous mast cell tumour. NLR= neutrophil to 
lymphocyte ratio. 
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Biochemical results were not available for one dog with a HG MCT. No 
significant difference was found when comparing either the individual 
components of the AGR or the AGR itself between LG and HG MCTs. Statistical 
comparison of absolute counts, NLR and AGR between tumour grades are shown 
in Table 3-3.  
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Grade 
Test  
All 
 
High
grade 
Low 
Grade 
p-value 
Albumin concentration (g/l) 32 
(21-36) 
29 
(21-36) 
32 
(27-36) 
0.413 
Globulin concentration (g/l) 34 
(27-45) 
34 
(27-45) 
33.5 
(28-43) 
0.318 
AGR 0.94 
(0.6-1.25) 
0.86 
(0.6-1.09) 
0.94 
(0.71-
1.25) 
0.061 
Absolute neutrophil count 
(x109/l) 
6.66 
(3.2-
15.18) 
8.32 
(3.62-
15.18) 
6.48  
(3.2-
12.01) 
0.053 
Absolute lymphocyte count 
(x109/l) 
1.16 
(0.21-
3.25) 
0.85 
(0.21-
1.34) 
1.22 
(0.65-
3.25) 
0.001* 
NLR 6.00 
(1.42-
29.07) 
9.15 
(3.83-
29.07) 
5.59 
(1.42-
8.89) 
0.000* 
Table 3-3 Median values and (ranges) for biomarkers of interest 
of dogs with high and low grade mast cell tumours. AGR=albumin 
to globulin ratio, NLR=neutrophil to lymphocyte ratio, * denotes a 
significant result 
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Univariate analysis was then performed, with the aim of identifying factors 
which could be built into a multivariable model to identify factors which could 
predict MCT grade. Fourteen variables were initially assessed for their 
association with MCT grade (Table 3-4). Twelve parameters (NLR, absolute 
lymphocyte count, age, tumour size, absolute neutrophil count, presence of 
lymph node metastasis, AGR, WHO tumour stage, presence of clinical signs, 
albumin concentration, globulin concentration and tumour location) were found 
to have a P value under 0.2 and were then included in the multivariable model. 
Sex and neutered status had P values above 0.2 and were not included.  
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Factor Odds Ratio (95% 
Confidence 
Interval) 
P value 
Age  1.47 (1.13-1.94) 0.001* 
Neuter Status  0.643 
Neutered relative to 
Entire 
1.34 (0.38-4.75)  
Sex          0.242 
Female relative to male 0.47 (0.13-1.71)  
Tumour Location  0.169* 
Body relative to Head 3.5 (0.66-18.49)  
Extremity relative to 
Head 
0.67 (0.14-3.11)  
Multiple relative to Head 0.44 (0.04-4.62)  
Limb relative to Body 0.19 (0.03-0.98)  
Multiple relative to Body 0.12 (0.01-1.41)  
Multiple relative to Limb 0.65 (0.06-6.80)  
Tumour Size 1.04 (1.01-1.07) 0.006* 
Lymph Node Metastasis 5.25 (1.35-20.47) 0.018* 
WHO stage  0.054* 
II relative to I 4.86 (1.21-19.57)  
III relative to I 0.61 (0.07-5.66)  
III relative to II 0.12 (0.01- 1.33)  
Clinical Signs 4.4 (0.94-20.66) 0.065* 
Neutrophil Count 1.39 (1.04-1.84) 0.015* 
Lymphocyte Count 0.02 (0.00-0.29) 0.000* 
NLR 1.83 (1.21-2.76) 0.000* 
Albumin Concentration 0.83 (0.67-1.04) 0.097* 
Globulin Concentration 1.11 (0.95-1.30) 0.163* 
AGR 0.04 (0.00-0.70) 0.027* 
Table 3-4: Showing the univariate logistic regression identifying 
factors significant in predicting mast cell tumour grade. A factor with 
a value of p<0.20 was considered for a multivariate stepwise logistic 
regression analysis. * denotes p<0.2 and factor part of multivariable 
analysis. WHO= World Health Organisation. NLR= neutrophil to 
lymphocyte ratio. AGR= albumin to globulin ratio. 
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NLR and age remained within the final multivariable model. For each extra year 
of age the likelihood of HG MCT increased by 1.67 times (95% confidence 
interval: 1.08-2.59; p-value =0.005). Each unit increase in NLR was associated 
with an increase in the likelihood of HG MCT of 2.03 times (95% confidence 
interval- 1.24- 3.35; p-value < 0.001) (Table 3-5). To assess whether the data 
conflicted with assumptions made by the model, the Hosmer-Lemeshow 
goodness of fit test was performed. This provided no evidence of a lack of fit 
(p=0.128).  
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Factor Odds Ratio (95% 
Confidence 
Interval) 
P value 
NLR 2.03 (1.24-3.35) <0.001 
Age  1.67 (1.08-2.59) 0.005 
Table 3-5: Stepwise multivariate logistic regression 
identifying factors which can predict mast cell tumour 
grade. All factors with a p<0.2 on univariate analysis were 
considered. Hosmer Lemeshow goodness of fit test- p=0.128. 
NLR= neutrophil to lymphocyte ratio. 
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The identification of a predictive cut-off value for each biomarker was 
considered to be clinically useful. In order to facilitate this, ROC curve analysis 
indicated that the area under the curve was 0.84 for NLR (Figure 3-2). Analysing 
the data produced by this test, a NLR threshold value of 5.67 gave a sensitivity 
of 85.7% and a specificity of 54.2% for predicting HG disease, correctly 
classifying 61% of MCTs. When the same test was performed using the AGR, the 
area under the curve for was not deemed high enough to be a useful 
discriminatory test (Figure 3-3). 
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Figure 3-2: Receiver operator characteristics curve for neutrophil 
to lymphocyte ratio, evaluating ability to predict mast cell tumour 
grade. Area under the curve= 0.84 (confidence interval 0.70-0.97). 
ROC= receiver operating characteristic.  
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Figure 3-3: Receiver operating characteristics curve for albumin 
to globulin ratio evaluating ability to predict mast cell tumour 
grade. Area under the curve= 0.67 (confidence interval 0.50-0.84). 
ROC= receiver operating characteristic 
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3.2 Comparing the Serum Proteome of High and Low Grade Canine 
Cutaneous Mast Cell Tumours 
3.2.1. Introduction 
Rather than just focussing on biomarkers already identified in the literature, the 
second aim of the thesis was to identify novel serum biomarkers to help separate 
LG from HG MCT and to separate MCT from controls.  
The differing molecular mechanisms occurring within LG and HG MCTs induce 
changes in the transcription and translation of proteins involved in a wide range 
of functions, such as cell motility, proliferation, metastasis and stress responses 
within the tumour (Schlieben et al . 2012). MCT result in changes to serum acute 
phase proteins such as C-reactive protein and α-1 acid glycoprotein which are 
increased above reference ranges (Chase et al ., 2012). Despite this, little is 
known regarding more detailed changes to the serum electrophoretogram and 
the serum proteome, especially any differences between LG and HG MCT.  
Differences between globulin fractions have been identified in canine lymphoma 
using 1D-SPE (Atherton et al., 2013b). In order to assess whether similar 
differences were present in MCT, the first part of this results section shows how 
1D-SPE was performed on 20 dogs with MCT to create electrophoretograms on 
the basis of densitometric scanning to analyse concentrations of protein 
fractions. In order to assess which specific proteins contributed to any 
differences identified using the 1D-SPE technique, and therefore to identify 
novel biomarkers of MCT and to compare serum changes to those within MCT 
tissue (Schlieben et al ., 2012) a more in depth method of analysis was required. 
Based on its successful application in dogs with lymphoma, a previously 
described (Atherton et al ., 2013b) method of further protein separation using 
2D-PAGE and MS was then used on six of these tumour bearing dogs and the 
results are presented in the second part of this section.  
1D-SPE was repeated to allow a primary method of separation in preparation for 
MS. 2D-PAGE without isoelectric focusing was then used to allow sufficient 
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separation to allow MS and identification of individual proteins within the serum 
samples of dogs with MCT. The ultimate aim was identification of both 
quantitative differences in serum protein fractions between LG and HG MCT and 
control cases as well as the presence or absence of specific serum proteins, 
which could identify discriminatory biomarkers for HG MCTs. 
3.2.2. Case Selection 
Twenty dogs with MCT which met inclusion criteria listed in the methods section 
2.1.1 were selected retrospectively on the basis of having the expected clinical 
outcome predicted for their tumour grade (e.g. no recurrence or metastasis for 
LG MCT and vice versa for HG MCT) and sufficient serum left to allow analysis. 
This included 12 LG MCT and eight HG MCT. In the LG group, there were three 
each of boxers and crossbreeds, two Labrador Retrievers and one each of golden 
retriever, cocker spaniel, beagle and Border collie. There were seven male 
entire, three female neutered and two male neutered dogs. Median age was 
eight years with a range of three to eleven years. Median total protein was    
63.5 g/l (range 62-72 g/l). 
Of the eight dogs with a HG MCT which were included, there were four 
crossbreed dogs, two Labrador retrievers and one each of Jack Russell terrier 
and Staffordshire bull terrier. There were three male entire and female 
neutered dogs and two male neutered dogs. Median age was 8.5 years with a 
range of five to 14 years. Median total protein was 66.5 g/l (range 57-78 g/l).  
Due to the requirements for each laboratory to establish their own reference 
ranges for 1D-SPE (Tappin et al ., 2011), published ranges could not be used to 
assess differences in the serum electrophoretogram between control and LG and 
HG MCT groups. Therefore, the serum from six control dogs was used to establish 
normal values for each protein fraction. The demographics of the three groups 
of dogs - control, LG MCT and HG-MCT are shown in Table 3-6. Of the six control 
dogs, there were three flat-coated retrievers, one Labrador retriever, one 
Leonberger and one greyhound. Four were male neutered and two female 
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neutered dogs. Median age was 3.5 years with a range of two to five years. 
Median total protein concentrations for this group was 63g/l (range 61-70g/l). 
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 # Age Sex Breed  
 
Total 
Protein 
Biochemical 
abnormalities  
Haematological 
abnormalities 
NLR MCT size  MCT 
location  
Clinical 
signs  
MCT stage 
Control 6 3.5  
(2-5) 
4 FN 
2 MN 
Flat-coated 
retriever (n=3) 
greyhound, 
Leonberger (both 
n=1) 
63  
(61-70) 
None Increased Hb (n=1) 4.63 
(3.65-
5.10) 
N/A N/A N/A N/A 
Low 
Grade  
12 8 
(3-11) 
8 ME 
3 FN 
2 MN 
 
Boxer dog, 
crossbreed (n=3),  
Labrador retriever 
(n=2), golden 
retriever, cocker 
spaniel, beagle, 
Border collie (n=1) 
63.5 (62-
72) 
Hypophosphate
mia (n=11), 
Increased AST 
(n=3), 
hyperglycaemia, 
hypoalbuminemi
a, increased ALT 
(n=1) 
Lymphopenia 
(n=4), increased 
MCH (n=2). 
Increased Hb, 
decreased Hb, 
increased MCV, 
leucocytosis (n=1) 
6.54 
(2.91-
8.89) 
18 
(9-40) 
Extremity 
(n=10), 
head/neck,  
other 
(n=1) 
Pruritus 
(n=1) 
Stage I (10) 
Stage II (2) 
High 
Grade 
8 8.5 
(5-14) 
3 FN 
3 ME 
2 MN 
Crossbreed (n=4), 
Labrador retriever 
(n=2), Jack Russell 
terrier, 
Staffordshire bull 
terrier (n=1). 
66.5 
(57-78) 
Hyperglycaemia 
(n=5), increased 
AST, 
hypophosphate
mia (n=3), 
hypoalbuminemi
a (n=2), 
increased ALT, 
hypocalcaemia 
(n=1) 
Lymphopenia 
(n=6), leucocytosis 
(n=3), 
neutrophilia, 
thrombocytosis 
(n=1) 
9.83 
(6.20-
28.6) 
36 
(12-140) 
Other (n=4), 
extremity 
(n=2), 
head/neck, 
multiple 
(n=1) 
Pruritus 
(n=1) 
Stage I (3) 
Stage II (4) 
Stage III (1) 
Table 3-6: Demographics and tumour specifics in groups of healthy control, low grade and high grade mast cell tumour cases. Age in 
years, total protein in g/l, MCT size in millimetres, MCT Stage refers to the World Health Organisation staging system (Owen, 1980). ALT= 
alanine aminotransferase, AST= aspartate aminotransferase, FE= female entire, FN= female neutered, Hb= haemoglobin, MCH= mean 
corpuscular haemoglobin, MCT= mast cell tumour, ME= male entire, MN= male neutered. Number values are shown as median values and 
(range).  
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Dog age differed significantly different between the control and LG (p=0.03) and 
control and HG MCT groups (p=0.01), but not between HG and LG MCT groups 
(p=0.473). Tumour size was significantly different between HG and LG MCT 
groups (p=0.012). 
Although dogs with MCT had some haematological and biochemical 
abnormalities, none were considered clinically significant. An increased 
haemoglobin concentration was identified in one control dog, which may have 
represented a normal value for the breed (greyhound). 
NLR was significantly different between HG and LG MCT groups (p=0.007), HG 
and control groups (p=0.011) and LG and control groups (p=0.04). 
However, no significant difference in serum total protein concentration was 
found between the three groups (p=0.419). No dogs had either an increased or 
decreased total protein concentration (range 50-78 g/l). 
3.2.3. One-dimensional serum protein electrophoresis 
Median values of absolute concentrations within the six protein fractions are 
shown in Table 3-7. Concentration of α-2 proteins were significantly increased in 
HG compared to LG MCT (p=0.031). Concentration of α-2 (p=0.043) and β-1 
(p=0.04) fractions were increased in the HG MCT group compared to controls. 
Concentration of β-2 proteins was significantly decreased in HG compared to 
controls (p=0.02)  
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Fraction Control  
median (range) 
g/l 
Low Grade MCT 
median (range) 
g/l 
High Grade MCT 
median (range) 
g/l 
Albumin 48.2 (34.9-51.8) 43.0 (36.4-47.32)* 42.8 (34.6-45.32)* 
α-1 4.0 (3.3-5.4) 4.4 (3.9-5.4) 5.0 (3.4-6.1) 
α-2 17.6 (12.4-19.1) 17.6 (14.4-21.3) 19.9 (17.8-23.4)*† 
β-1 6.8 (5.5-6.8) 9.4 (7.0-13.6)* 11.3 (6.1-18.0)* 
β-2 13.4 (13.1-15.1) 13.3 (8.8-21.1) 11.1 (10.2-16.7)* 
γ 10.9 (7.3-12.7) 9.8 (8.4-14.0) 8.8 (6.7-13.2) 
Table 3-7: Relative serum protein fractions derived from one-dimensional 
serum protein electrophoresis in healthy dogs and those with low and high 
grade mast cell tumours. MCT=mast cell tumour. * denotes result significantly 
different from control group. †denotes result significantly different from low 
grade MCT group. 
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3.2.4. Two-dimensional polyacrylamide gel electrophoresis 
After 1D-SPE, three each of control, LG MCT and HG MCT serum samples were 
selected for further protein separation and MS, as best representing the median 
relative protein concentrations for each respective group. Details of each dog 
are presented in Table 3-8. One-dimensional gels were repeated for the nine 
dogs, followed by PAGE as outlined in the methods section 2.3.2.  
For each group of three samples (control, LG MCT, HG MCT), the stained PAGE 
gels were compared by visual inspection to establish the pattern of bands which 
could be expected as representative of the group. 
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Dog  Group Age 
(years) 
Sex Breed Tumour 
Size  
Primary 
Tumour 
Location 
NLR Staging Staging 
Abnormalities 
WHO 
Stage 
Treatment  Outcome 
1 Control  5 FN Leonberger   5.10      
2 Control 2 MN Flat-coated 
retriever 
  3.65      
3 Control 3 MN Greyhound   3.82      
4 LG 7 ME Labrador 
retriever 
9 Head/ne
ck 
4.53 CXR, AUS, 
cLN 
None I Excision MCT Alive 249 days, no 
recurrence 
5 LG 11 FN Crossbreed 22 Extremit
y 
8 CXR, AUS, 
cLN 
Metastatic 
superficial 
cervical LN 
II Excision MCT & LN  Alive 566 days, no 
recurrence 
6 LG 11 FN Crossbreed 15 Extremit
y 
5.57 CXR, AUS. None I Excision MCT Alive 389 days, no 
recurrence 
7 HG 9 FN Crossbreed 25 Extremit
y 
8.7 CXR, cAUS, 
hLN. 
None I Excision MCT 
VBL/Pred 
Dead 1030 days, 
recurrent disease 
8 HG 14 FN Crossbreed 60 Other 28.63 CXR, cAUS, 
hLN. 
Metastatic 
axillary LN  
II Excision MCT & LN. 
VBL/Pred 
Dead 310 days, 
recurrent disease 
9 HG 8 MN Labrador 
retriever 
32 Other 10.5 CXR, cAUS,  None I Pred Dead 30 days, 
progressive disease 
Table 3-8: Case details of dogs selected for two-dimensional serum protein electrophoresis and mass spectrometry. AUS= abdominal 
ultrasound, cAUS=abdominal ultrasound with FNA and cytology of liver and spleen, CXR= thoracic radiographs, HG= high grade mast cell 
tumour, FE=female entire, FN=female neutered, LG= low grade mast cell tumour, LN= lymph node, cLN=FNA and cytology of local 
lymph node, hLN histopathology of local lymph node, MCT=mast cell tumour, ME=male entire,  mm=millimetres, MN=male neutered, 
Pred= prednisolone, VBL= vinblastine. Staging using World Health Organisation system (Owen 1980). 
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3.2.4.1. Controls 
Ten protein bands were identified in dog 1, with 15 bands identified from 
dogs 2 and 3. A protein band was identified in 21 unique positions, with seven 
of these bands identified in all gels, five in two gels and nine only in one gel 
(Figure 3-4). To establish which proteins migrated in each band, selected 
bands were excised for MS, focussing on those found in more than one gel and 
taking the band from whichever gel had the darkest staining band. Due to 
financial constraints, it was not possible to process all bands seen or to 
compare proteins present within bands on the same position in two or more 
gels. Albumin bands were not submitted as these proteins were less likely to 
yield potential biomarkers. Eleven bands were excised and MS was performed 
as described in the methods section 2.3.3. This analysis identified 22 proteins 
(Table 3-9). Of these proteins, albumin was identified in both the α-1 and β-1 
fractions. There were five forms of immunoglobulin within the β and γ 
fractions and three complement related proteins from the β-1 fraction. Two 
histone proteins were present within the β-2 fraction. Of the 11 other 
proteins identified, one was as yet uncharacterised, three are involved in iron 
transport and haptoglobin, an acute phase protein, was identified in the α-2 
fraction.   
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Figure 3-4: Image of two-dimensional serum protein electrophoresis gels from three control dogs. Each band and protein fraction has 
been labelled. Bands present in more than one gel were then selected to perform mass spectrometry. Dog 1 was a 5 year old female 
neutered Leonberger, dog 2 a 2 year old, male neutered flat-coated retriever and dog 3, a 3 year old, male neutered greyhound. 
Excised bands submitted for mass spectrometer analysis: dog 1- bands 3,7 and 8; dog 2- bands 6,7,8,9,11,14 and 15. 
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Protein 
Fraction 
Protein identified by mass 
spectrometry 
Dog(s) Band(
s) 
MOWSE 
score(s) 
α-1 
β-1 
albumin 1  
2 
3,  
8, 9  
1513,  
69, 107 
α-1 alpha-1B-glycoprotein 1 3 102 
α-1 haemoglobin subunit alpha 1 3 112 
α-1 kininogen-1 isoformX2 1 3 94 
α-2 
β-1 
γ 
apolipoprotein A-I 2 7  
11 
15 
1511 
323 
92 
α-2 
β-2 
glial fibrillary acidic protein 
isoformX2 
2 
1 
7 
7 
132 
83 
α-2 haptoglobin beta chain 2 6 65 
β-1 C4b-binding protein alpha chain 
isoform X1 
2 8 119 
β-1 complement C3 1,  
2 
7,  
8, 9, 
11 
225,  
86, 986, 
102,  
β-1 complement C4-A 2 8 71 
β-1 haemopexin 2 9 153 
β-1 
γ 
immunoglobulin lambda-like 
polypeptide 5-like 
2 11 
15 
143 
338 
β-1 
β-2 
serotransferrin isoform 1 1 
 2 
7 
8, 9 
1527  
1385, 
186 
β-2 14-3-3 protein sigma 1 8 78 
β-2 histone H2B type 1-N-like 1 8 74 
β-2 histone H4-like sequences 1 8 186 
β-2 immunoglobulin gamma heavy 
chains 
1,  
2 
8 
14 
149, 146 
306, 190 
β-2 immunoglobulin heavy chains 1 7 
8 
83,  
116 
β-2 immunoglobulin heavy chain 
variable region 
2 
  
14 122 
β-2 junction plakoglobin 1 8 95 
β-2 plakophilin-1 1 8 120 
β-2 uncharacterized protein 1 8 225 
Table 3-9: Proteins identified by mass spectrometry from the serum of 
healthy control dogs after separation using a method of two-dimensional 
electrophoresis. Italic text denotes that proteins predicted from known 
genomic sequences. MOWSE= Mascot molecular weight search. 
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3.2.4.2. Low Grade Mast Cell Tumours 
Nineteen of the 21 bands identified in the control population were also 
present on comparison of the three gels from the LG MCT dogs (Figure 3-5). 
However, 22 unique positions were additionally identified in LG MCT cases. 
Seven bands were identified in all gels, six in two gels and nine in one gel. As 
for controls, globulin bands for MS were excised from whichever gel the band 
stained most strongly, with 11 excised in total, identifying 17 proteins (Table 
3-10).  Of these 17 proteins, five were immunoglobulins, albumin was 
identified and three were proteins involved in oxygen transport. Complement 
C3 and haptoglobin were also found, within the β and α-2 fractions 
respectively.  
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Figure 3-5: Image of two-dimensional serum protein electrophoresis gels from three dogs with low grade mast cell tumours. Each 
band and protein fraction has been labelled. Bands present in more than one gel were then selected to perform mass 
spectrometry. Dog 4, a 7 year old, male entire golden retriever with a 9mm mast cell tumour of the head/neck region; dog 5, an 
11 year old female neutered crossbreed with a 22mm MCT on an extremity; dog 6, another 11 year old crossbreed with a 15mm 
MCT on an extremity. All were treated with surgery with no reported recurrence for a minimum of 249 days. Excised bands 
submitted for mass spectrometer analysis: dog 3- band 7; dog 5- band 4; dog 6- bands 10,12,13,14,15,17,18 and 19 
89 
 
 
 
 
  
Protein 
Fraction 
Protein identified by mass 
spectrometry 
Dog Band 
(s) 
MOWSE 
Score(s) 
α-1 serpin peptidase inhibitor, clade A 
(alpha-1-antiproteinase) a 
5 4 391 
α-1 kininogen-1 isoformX2 5 4 218 
α-1  alpha-1 antitrypsin 5 4 105 
α-2 apolipoprotein A-I 6 10 1877 
α-2 haptoglobin 4 7 354 
β-1 
β-2 
Complement C3 6 12, 14 656, 105 
 
β-1 haemopexin 6 12 180 
β-2 
γ 
albumin 6 13, 17 274, 220 
β-2 Immunoglobulin heavy chain variable 
region 
6 13 
18 
69, 69 
98 
β-2 
γ 
immunoglobulin gamma heavy chains 6 15 
18 
178, 113, 
112 
305, 282, 
253, 96 
β-2,  
γ  
serotransferrin isoform 1 6 14, 15  
17 
473, 75 
1076 
β-2  
γ 
Immunoglobulin kappa chain variable 
region a 
6 16 
19 
83 
81 
β-2  
γ 
immunoglobulin lambda-like 
polypeptide 5-like 
6 16 
17, 19 
195 
78, 274 
γ beta-2-glycoprotein 1 precursor a 6 18 85 
γ haemoglobin subunit β 6 17, 19 358, 101 
γ hypothetical proteins 6 19 94, 94 
γ immunoglobulin lambda light chain 
variable region a 
6 19 75 
Table 3-10: Proteins identified from the serum of dogs with low grade 
cutaneous mast cell tumours after separation using a method of two-
dimensional electrophoresis. Italic text denotes that proteins predicted 
from known genomic sequences. a denotes proteins not found in the serum 
of healthy control dogs. MOWSE= Mascot molecular weight search. 
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3.2.4.3. High Grade Mast Cell Tumours 
Fifty-three bands were identified from HG-MCT cases of which thirty were 
unique. Eleven of these unique bands were identified in all gels, one band in 
two gels and eighteen on one gel (Figure 3-6). Gels for dogs 7 and 8 had a 
similar number of bands to control dogs but dog 9 contained many of these 
same bands but also all 18 of the unique bands in the HG cohort. These were 
particularly in α2, and γ fractions. This dog had the shortest survival of the 
HG MCT. Fifteen globulin bands were excised and 30 proteins were identified 
(Table 3-11). Due to the number of unique protein bands seen, the majority 
of these were from dog 9. Of these proteins, six were immunoglobulins, 
haptoglobulin and albumin were also identified, as were three complement 
related proteins. There were several proteins of interest, which have 
previously been found to be implicated in cancer pathogenesis. These were 
inter-α-trypsin inhibitor heavy chain H1 isoform X2, leucine-rich α-2-
glycoprotein, plasma protease C1 inhibitor, pregnancy zone protein, α-2-
macroglobulin isoform X2 and α-2 heat-shock glycoprotein (Starcevic, Jelic-
Ivanovic and Kalimanovska, 1991; Bourguignon et al ., 1999; Jae et al ., 2009; 
Andersen et al ., 2010; Atherton et al ., 2013b; Adeola et al ., 2015). 
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Figure 3-6: Image of two-dimensional serum protein electrophoresis gels from three dogs with high grade 
mast cell tumours. Each band and protein fraction has been labelled. Bands present in more than one gel 
were then selected to perform mass spectrometry. Dog 7 was a 9 year old female neutered crossbreed with 
a 25mm MCT on an extremity; dog 8, a 14 year old female neutered crossbreed with a 60mm tumour on the 
trunk and dog 9, an 8 year old male neutered Labrador retriever, with a 32mm tumour of the trunk. All 
dogs died due to progressive MCT. Excised bands submitted for mass spectrometer analysis: dog 7- bands 
6,7 and 9; dog 9- bands 5,7,8,9,10,11,14,,24,26,27 
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Protein 
Fraction 
Protein identified by mass 
spectrometry 
Dog(s) Band(s) MOWSE 
Score(s) 
α-1,  
α-2, 
α-2 
β-1 
β-1 
γ 
albumin 9 
9 
7 
9 
7 
9 
5,  
8, 9, 10 
6, 7 
14 
9 
24 
206,  
113, 84, 
77 
107, 201 
107 
201 
71 
α-1 α-1-antiproteinase-like a 9 5 102 
α-1 
α-2 
α-2-HS-glycoprotein a b 9 5, 10 72, 156 
α-1 kininogen-1 isoformX2 9 5 115 
α-1 
α-2 
serpin peptidase inhibitor, 
clade A a 
9 
9 
5 
10 
105, 
69 
α-2 α-2-macroglobulin a b 9 7, 8 80, 317 
α-2 angiotensinogen  a b 9 10 94 
α-2 antithrombin-III isoform 1   a b 9 10 240 
α-2 apolipoprotein A-I 9, 7 10, 6 212, 1103 
α-2 fetuin-B a b 9 10 75 
α-2 glial fibrillary acidic protein 
isoformX2 b 
9 7, 8 105, 92 
α-2 haptoglobin 7 7 342 
α-2 
β-1 
haemopexin 7 
7 
6 
9 
145 
145 
α-2 
β-1 
γ 
immunoglobulin gamma heavy 
chains 
7 
9 
9 
8 
10 
26 
78 
246, 131 
802, 539, 
385, 331 
α-2 inter-α-trypsin inhibitor heavy 
chain H1 isoform X2 a b 
9 7 221 
α-2 leucine-rich α-2-glycoprotein a b 9 10 73 
α-2 maltase-glucoamylase, 
intestinal a b 
9 7 78 
α-2 plasma protease C1 inhibitor a b 9 9 113 
α-2 pregnancy zone protein a b 9 8 84 
β-1 C4b-binding protein α chain 
isoform X1 b 
9 14 88 
β-1 
 
γ 
complement C3 9 
7 
9 
9 
14 
8, 9 
24 
27 
482 
378, 594 
819 
76 
β-1 
γ 
complement C4-A b 9 
9 
14 
24 
84 
203 
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β-2 
γ 
serotransferrin isoforms 7 
9 
10, 11 
24, 26 
1768, 166 
1006, 73 
γ beta-2-glycoprotein 1 
precursor  a 
9 26 86 
γ Immunoglobulin heavy chain 
variable region 
9 26 195, 172, 
161, 77 
γ immunoglobulin lambda light 
chain variable region a 
9 27 
182, 75 
γ immunoglobulin lambda-like 
polypeptide 5-like  
9 27 
126 
γ putative V-set and 
immunoglobulin domain-
containing-like protein a b 
9 26 
89 
γ Immunoglobulin kappa chain 
variable region a 
9 27 
130 
Γ uncharacterised protein 9 27 194 
Table 3-11: Proteins identified from the serum of dogs with high 
grade cutaneous mast cell tumours after separation using a 
method of two-dimensional electrophoresis. Italic text denotes 
that proteins predicted from known genomic sequences. a denotes 
proteins not identified in the serum of healthy control dogs, b 
denotes proteins not identified in the serum of dogs with low 
grade, cutaneous mast cell tumours. MOWSE= Mascot molecular 
weight search. 
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In total, 15 proteins were identified from the serum of dogs with MCT, which 
were not identified in the serum of normal dogs, both from the control cases in 
this study and also from healthy dogs from a previous report (Atherton et al ., 
2013a). Of the proteins listed in table 3-11, α-1-antiproteinase-like and serpin 
peptidase inhibitor, clade A were considered to be different parts of the same 
protein and have been denoted as α-1-antiproteinase. The vast majority (10) of 
these, were found within the α-2 fraction. Eleven of the 15 were identified in 
HG MCT samples only (Table 3-12).  
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Protein (alternative 
names) 
Protein 
Fraction 
Function Changes in disease 
α-1-antiproteinase 
(serpin family A 
member 1, α-1 
antitrypsin) 
α-1 Serine protease 
inhibitor. 
Acute phase protein 
with negative feedback 
on the inflammatory 
response (Jain, Gautam 
and Naseem, 2011) 
Serum marker of human 
cancer (Varela and Lopez 
Saez 1995) 
 
α-2-HS-
glycoprotein a,b 
α-2 Endocytosis 
Brain development 
Formation of bone 
tissue 
Serum marker of human 
breast cancer (Jae et al ., 
2009) 
α-2-macroglobulin 
a,b 
α-2 Protease inhibitor 
Binds chymase released 
from mast cells 
(Raymond et al ., 2009) 
Acute phase protein 
with negative feedback 
on the inflammatory 
response (Jain, Gautam 
and Naseem, 2011) 
Protects IL-6 (Murata, 
Shimada and Yoshioka, 
2004)  
Identified in the serum of 
cats and dogs with 
lymphoma (Atherton et 
al ., 2013b; Gerou-
Ferriani et al ., 2011) 
angiotensinogen a,b α-2 Cleaved by renin in 
response to 
hypotension 
 
antithrombin-III 
isoform 1 a,b 
α-2 Serine protease 
inhibitor 
 
fetuin-B a,b α-2 Cysteine protease 
inhibitor 
 
inter-α-trypsin 
inhibitor heavy 
chain H1 isoform X2 
a,b 
α-2 Implicated in multiple 
inflammatory diseases 
H1 isoform is produced 
by mast cells and 
involved in malignant 
transformation in human 
pulmonary neoplasia 
(Bourguignon et al ., 
1999). 
maltase-
glucoamylase, 
intestinal 
α-2 Intestinal brush-border 
enzyme 
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leucine-rich α-2-
glycoprotein a,b 
α-2 Expressed during 
granulocyte 
differentiation 
Protein to protein 
interaction 
Signal transduction 
Cell adhesion and 
development 
Increased concentration 
in serum of humans with 
ovarian and lung cancer 
(Andersen et al ., 2010) 
Increased serum 
concentration in human 
pancreatic cancer 
independent of increases 
in acute phase proteins 
(Kakisaka et al ., 2007) 
plasma protease C1 
inhibitor a,b 
α-2 Regulates complement 
activation 
Serine protease 
inhibitor  
Acute phase protein 
with negative feedback 
on the inflammatory 
response (Jain, Gautam 
and Naseem, 2011) 
Increased serum 
concentrations in human 
cancer  (Starcevic, Jelic-
Ivanovic and 
Kalimanovska, 1991) 
pregnancy zone 
protein a,b 
α-2 Proteinase inhibitor Increased serum 
concentrations in human 
prostatic carcinoma  
(Adeola et al ., 2015) 
Upregulated in human 
and canine osteoarthritis 
(Gharbi et al ., 2013) 
β-2-glycoprotein 1 
precursor 
(apoliprotein H) 
β-2 Contributes to innate 
immunity 
Lipoprotein metabolism 
Coagulation 
 
putative V-set and 
immunoglobulin 
domain-containing-
like protein a,b 
γ Immunoglobulin- 
acquired immunity 
 
immunoglobulin 
lambda light chain 
variable region 
γ Immunoglobulin- 
acquired immunity 
 
Immunoglobulin 
kappa chain 
variable region 
γ Immunoglobulin- 
acquired immunity 
 
Table 3-12: Description of proteins identified in the serum of dogs 
with cutaneous mast cell tumours, not identified in the serum of 
healthy control dogs.   
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4 Discussion 
The research undertaken in this thesis has identified a number of potential 
biomarkers for MCT. There are both biomarkers which could have clinical 
application in predicting the biological behaviour of a MCT as well as proteins 
which are not at present readily identifiable, but which may be relevant 
biomarkers when considering pathogenesis and/or treatment.  
4.1 Neutrophil to lymphocyte ratio and albumin to globulin ratio 
Within the studied population of 61 dogs, the NLR had good discriminatory 
ability in distinguishing between histopathological (Kiupel) grade of MCT. This 
has relevance as it may alter the investigative procedures required before 
treatment or may guide treatment decisions. The NLR utilises the role of 
inflammation in both initiating and propagating neoplastic change (Hanahan and 
Weinberg, 2011; Sideras and Kwekkeboom, 2014; Raposo et al ., 2015). A 
critical review of over 60 studies containing more than 37,000 human patients 
concluded that the NLR is useful in determining prognosis and disease stage for 
a variety of solid neoplasms (Guthrie et al ., 2013).  
Given the complexity at both local and systemic levels, it is surprising that this 
‘crude’ biomarker has shown utility in a wide range of neoplasms (Sideras and 
Kwekkeboom, 2014). The role of inflammation in any cancer is remarkably 
complex with both suppression and stimulation of very similar arms of the 
inflammatory response present within the tumour microenvironment (Raposo et 
al ., 2015). The use of the NLR in MCTs is further complicated given that mast 
cells are leucocytes, can create a marked inflammatory response (Blackwood et 
al ., 2012) and are involved in chemotaxis and interaction with both neutrophils 
and lymphocytes (Salamon et al ., 2005).  
There is an indication for a biomarker which can be calculated pre-biopsy and 
has good discriminatory ability between LG and HG MCT to identify dogs which 
would benefit from a pre-treatment incisional or core biopsy to confirm 
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histopathological grade. In order to determine histopathological grade a biopsy 
is required. Typically, biopsy procedures other than a FNA are rarely performed 
on MCTs prior to surgery (Risselada, Mathews and Griffith, 2015). This may be 
due to concerns over increased complication rates due to mast cell 
degranulation or coagulopathies which can be present, financial considerations 
or that cytology is diagnostic in 96% of MCTs (Baker-Gabb, Hunt and France, 
2003). In contrast, a complete blood count frequently forms part of a pre-
anaesthetic assessment or general health profile in dogs with neoplasia and 
therefore NLR can often be attained with no morbidity to the dog or financial 
cost to the owner. 
Current guidelines advise using the presence of factors associated with a more 
aggressive tumour as criteria for performing staging prior to surgery (Blackwood 
et al ., 2012; London and Thamm, 2012). The prevalence of regional metastasis 
is higher in tumours of a higher grade in this report and others (using the three-
tiered grading system) (Krick et al ., 2009; Warland et al ., 2014). An objective 
biomarker which can aid in identification of HG tumours could be incorporated 
into this algorithm. 
In human medicine, NLR is used to guide treatment decisions (Zou et al ., 2016) 
and this may also be applicable in canine MCTs. Current consensus guidelines for 
MCTs recommend larger surgical margins for higher grade tumours (using the 
three tiered grading system), although grade is often not known prior to surgery 
(Blackwood et al ., 2012). A discriminatory biomarker could therefore assist this 
decision making process. The NLR may also guide decisions such as the use of 
neo-adjuvant therapies, although objective data is currently lacking in this area 
in human medicine (Guthrie et al ., 2013).  
NLR was maintained within the multivariable linear regression model, with each 
one point increase in NLR resulting in a two fold increase in the risk of having a 
HG MCTs when values were adjusted for age. In this population, there is an 
overlap in NLR values between LG and HG MCTs and therefore a perfect cut-off 
for NLR does not exist. We chose a value (5.67) which was sensitive for HG 
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disease to reduce misclassification of HG MCTs. Two HG MCTs (14%) were 
misclassified using the proposed NLR threshold value; one from a dog which had 
a HG MCT completely excised three months prior to inclusion, but at point of 
inclusion into the data set, a markedly enlarged inguinal lymph node was 
identified without local recurrence. Lymph node metastasis may therefore 
stimulate alternative inflammatory pathways to a primary cutaneous tumour, 
with a differing impact on the NLR. The other misclassified HG MCT had ‘weak’ 
KIT staining and a low Ki-67 score (0.45), indicating the possibility of LG 
biological behaviour, although the KIT staining pattern was type III, which has 
been related to an aggressive biological behaviour (Kiupel et al ., 2004; Scase et 
al ., 2006). Approximately half (twenty-two of forty-eight) of LG tumours were 
misclassified using the proposed NLR threshold value. Of the tumours where Ki-
67 staining and KIT staining pattern was available, two of nine misclassified LG 
tumours had a high Ki-67 index (>1.8) and one of nine had a type III KIT staining 
pattern- both factors which can confer a higher biological grade (Kiupel et al ., 
2004; Scase et al ., 2006), whilst three of eight of the correctly classified LG 
MCTs had a high Ki-67 index and one of eight had a type III KIT staining pattern. 
The impact of this misclassification is that additional diagnostic testing may be 
performed on cases with LG MCT with a NLR above the threshold value which 
may not be required. However, staging may still be appropriate for these cases 
as LG MCT have metastatic potential.  
Age was maintained within the multivariable logistic regression model and an 
association between increasing age and more aggressive biological behaviour has 
previously been identified (Kiupel et al ., 2005). 
Adjusting for other factors within the multivariable linear regression model, 
tumour size was not found to be associated with grade of MCT (p=0.591). There 
were several limitations to the measurement of tumour size, each possibly 
resulting in type two error. The longest diameter was used as this is the value 
which was most frequently reported in clinical notes, however, volumetric 
assessment as previously used in MCTs (Stanclift and Gilson, 2008) may be more 
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useful, but was unobtainable from available information. Method of 
measurement was not recorded as to whether it was estimated, measured with 
a caliper or whether imaging modalities were used. The longest diameter of 
metastatic lymph nodes was included, although a smaller proportion a lymph 
node structure may be expected to be comprised of neoplastic cells than a 
primary tumour.  
There are conflicting reports regarding the validity of the World Health 
Organisation staging system for MCTs (Thamm, Mauldin and Vail, 1999; Kiupel et 
al ., 2005; Mullins et al ., 2006; Murphy et al ., 2006). Outcome variables were 
not assessed; however eight of nine dogs with multiple tumours had a LG MCT 
and there was a reduced probability of stage III tumours being HG than stage I 
or II disease on the univariate linear regression analysis (Table 3-4).   
The importance of MCT location on biological behaviour is unclear. Four main 
locations, including head and neck, trunk, inguinal and perineal, or extremity 
have previously been used to evaluate the difference between sites (Kiupel et 
al ., 2005). Differing systems have been used in recent reports however 
(Donnelly et al ., 2013; Smith et al ., 2015) and a standard method of reporting 
MCT location to allow comparison between reports may be beneficial.  Inguinal 
and perineal MCTs may have a worse prognosis in some studies (Sfiligoi et al ., 
2005) but not others (Cahalane et al ., 2004). In this population, MCTs located 
on the trunk (designated ‘other’) were found to have the highest median NLR.  
Forty-five percent (five of eleven) of MCTs on the body were HG, compared to 
23% (fourteen of sixty-two) of MCTs overall.  
AGR was not useful in discriminating between high and LG MCTs in this 
population of 61 dogs. This biomarker was chosen given its use in human 
neoplasia (Azab et al ., 2013) and lack of additional cost or stress in its 
attainment given the frequency of biochemical analysis in this cohort of dogs. 
Albumin is an acute phase protein and it might be expected that its 
concentration would be lower in HG MCTs which are more likely to be 
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inflammatory. Its concentration was not different between LG and HG in this 
cohort.  
Subsequent to this analysis, another study was conducted showing NLR not to be 
predictive of prognosis in a multivariable model for MCT (Skor et al ., 2017). In 
contrast, the neutrophil to eosinophil ratio was found to have prognostic 
significance. Using survival as an outcome variable for mast cell tumour is also 
problematic as the majority of dogs with MCT will not die as a result as a result 
of their disease. The eosinophil concentration was not assessed in the 
population of dogs in this thesis, however, examination of whether the 
neutrophil to eosinophil ratio could be used to predict grade and comparison to 
the NLR would be a potential avenue for future research.  
There were several limitations to the NLR and AGR research performed in this 
section. The case numbers presented are smaller than in thirty-two of thirty-
four human reports collated in a review of the clinical use of the NLR (Guthrie 
et al ., 2013). The number of dogs with HG MCTs (fourteen) was particularly 
small, however the proportion of high and LG MCTs was similar to that 
previously reported (Kiupel et al ., 2011). Full staging procedures were not 
performed in every dog, so the incidence of metastatic disease, especially the 
involvement of local lymph nodes may be higher than reported. FNA of gross 
MCTs was performed at varying times prior to referral and also within our 
institution. There are no data available on the effect of FNA on haematological 
and biochemical parameters, but it is possible that a local inflammatory 
reaction to FNA may alter either NLR or AGR. Although NLR has been used as a 
prognostic marker in many human neoplastic conditions (Guthrie et al ., 2013), 
survival analysis was not performed because of the small number of cases, the 
variety of treatment modalities used, long survival times for LG MCTs and lack 
of complete follow up information which made the outcome of questionable 
scientific value. A larger study examining the prognosis or disease free intervals 
in a population of dogs with the same grade of MCT, treated in the same 
manner would be required to determine whether the NLR could be used as a 
stand-alone prognostic factor for MCTs.  
102 
 
 
 
4.2 Serum protein electrophoresis 
Significant changes to the serum proteome of dogs with HG MCTs have been 
identified despite no overall increase in serum total protein concentrations.  
Changes in globulin fractions were found both with the affordable, accessible 
and available 1D-SPE and also 2D-PAGE protein separation and MS, using a 
previously described technique (Atherton et al ., 2013a).  
1D-SPE identified an increase in the α-2 protein concentrations in HG MCTs 
compared to LG MCTs and control dogs. Increased α-2 concentrations are found 
in dogs with other neoplasms, including lymphoma and hepatocellular carcinoma 
(Atherton et al ., 2013b; Tappin et al ., 2011). This protein fraction contains 
acute phase proteins which increase in concentration in many inflammatory 
conditions, including MCT (Tappin et al . 2011; Chase et al ., 2012). Given the 
increased number of proteins identified in this fraction in HG MCT cases using 
MS, it is likely that this difference is attributable to changes in a number of 
proteins, although quantification of individual proteins was not possible.  
Concentration of the β-1 fraction was increased in both HG and LG MCTs 
compared to control dogs. This fraction comprises transferrin, immunoglobulins 
and complement and is increased in many local and systemic neoplasms as well 
as both infectious and inflammatory conditions (Tappin et al ., 2011). No 
proteins were identified in the β-1 fraction of dogs with MCTs that were not also 
identified in the control population. This supports the hypothesis that 
differences in concentrations of particular fractions may be due mostly to 
changes in concentration of normal proteins rather than production of significant 
concentrations of novel or different proteins. 
Changes in protein fractions detected in 1D-SPE are likely to result from a non-
specific inflammatory response to MCT. It is possible that 1D-SPE will have a 
clinical utility in MCT since increased α-2 may suggest biological aggressiveness.   
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The pattern of 2D-PAGE protein bands was similar to that obtained by Atherton 
(2013a, b). The locations of complement proteins, kininogen and haptoglobin 
were similar amongst control dogs, LG and HG MCT groups and also to previous 
work analysing the serum of dogs with lymphoma. The fact that similar 
migration patterns were seen shows that this technique, when performed by 
different operators and using dogs with different tumour types is reproducible.  
Despite this reproducibility, more proteins were found in control dogs in this 
analysis than in the control dogs examined by Atherton (2013a) when this 
technique was used for the first time. Nine proteins found in control dogs were 
the same in both studies, but Atherton identified two proteins not seen in this 
study’s control population and conversely this thesis research identified 12 
proteins not identified by Atherton. This variation may be due to the difference 
between brands of agarose gel used in the two studies and slightly different 
running conditions or to differences in the control population although both 
studies used donor controls. Many proteins, including albumin, were identified in 
multiple fractions. The separation technique is subject to experimental variation 
in how bands are excised from the unstained agarose gel and combined for the 
PAGE so some proteins can appear to be in the wrong fraction, creating 
additional bands on some gels or additional proteins co-migrating within bands. 
Other reasons for proteins being identified in more than one fraction include 
fragmentation of proteins during processing, leading to migration within a 
different band. Post-translational modification, different protein isoforms and 
streaming of proteins within the gel can also be causes of this identification in 
more than one fraction. Haptoglobin was identified in a dog from the control 
population. This was also identified in the α-2 fraction of a dog with lymphoma, 
but not previously in the serum of healthy dogs (Atherton et al ., 2013a,b). 
Despite its status as an acute phase protein, the identification of haptoglobin in 
the serum of a normal dog is not surprising as it is a constitutive protein (Murata, 
Shimada and Yoshioka, 2004). 
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Examination of the protein migration pattern found using PAGE, revealed that an 
increased number of unique bands were found in one of the HG MCT dogs (dog 9) 
which was the dog with shortest survival time. This can be seen as a limitation of 
the study as a large proportion of the protein identification data arose from one 
dog.  Many of these proteins were within the α-2 and β-1 fractions, 
substantiating the 1D-SPE results. The other two HG MCT cases used for MS had 
longer survival times although both were euthanised due to MCT disease. These 
cases had fewer protein bands identified than the case with the shortest survival 
time. Cases were selected as having typical 1D-SPE results for their group and in 
retrospect it may have been more appropriate to this investigation to select 
cases with a more aggressive disease course. 
After MS analysis, 16 proteins were identified within the serum of dogs with 
MCTs which were not identified in healthy control dogs. Four of these were 
acute phase proteins: α-1-antiproteinase, α-2-HS-glycoprotein, α-2-
macroglobulin and plasma protease C1 inhibitor. One of these, α-1-
antiproteinase, a protein found to increase the migration and invasion of human 
gastric cancer cells (Kwon et al ., 2014) was identified in the α-1 fraction. This 
protein, also known as serpin peptidase inhibitor, clade A was found in band 4 
from dog 5. This protein has also been identified in the serum of dogs with 
lymphoma, using the same method and was in a similarly located band in the 
same protein fraction (Atherton et al ., 2013b). Although a similarly located 
band was identified within the control population this protein was not identified 
within it. Five of the 16 MCT specific proteins were proteinase inhibitors: α-1-
inhibitor, α-2-macroglobulin, antithrombin III, plasma protease C1 inhibitor and 
pregnancy zone protein. Proteinase inhibitors may be synthesised in response to 
an inflammatory state, but have also been associated with tumour pathogenesis, 
possibly by stimulating the production of matrix metalloproteases (Sueoka et al 
., 2005). α-2 macroglobulin binds chymase released by mast cells (Raymond et al 
., 2009) and provides negative feedback to an inflammatory response (Jain, 
Gautam and Naseem, 2011). α-2 macroglobulin has also been identified in the 
serum of dogs and cats with lymphoma (Gerou-Ferriani et al ., 2011, Atherton et 
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al ., 2013b;). Canine specific enzyme linked immunosorbent assays are available 
and identification in a larger cohort of dogs with MCT is indicated. Further 
exploration of the role of protease inhibitors in MCT is warranted to determine 
their role in this cancer.  
α-1-antiproteinase, α-2-HS-glycoprotein, leucine-rich α-2-glycoprotein, plasma 
protease C1 inhibitor and pregnancy zone protein have been identified in the 
serum of human patients with various neoplastic conditions and are used as 
biomarkers (Starcevic et al ., 1991; Varela and Lopez Saez 1995; Kakisaka et al 
., 2007; Jae et al ., 2009; Andersen et al ., 2010; Adeola et al ., 2015). 
Identification and quantification of these proteins in a wider cohort of MCT and 
control animals is indicated to assess their potential use as biomarkers.  
Inter-α-trypsin inhibitor heavy chain H1 isoform is one of three precursor 
proteins, typically produced in hepatocytes, which covalently bind to form inter-
α-trypsin inhibitor. The H1 isoform has been identified and may also be 
synthesised within mast cells and neoplastic pulmonary squamous cells 
(Bourguignon et al., 1999). Although a specific role has not been identified, 
inter-α-trypsin inhibitor contributes to malignant transformation (Bourguignon et 
al., 1999) and may be involved in the pathogenesis of MCT. This protein was 
identified within the α-2 fraction (Figure 3-6, Dog 9 Band 7) with a band not 
identified in LG MCT or control samples and was the highest MOWSE score 
protein identified within this band. Additional 2D-PAGE and MS, 
immunohistochemistry or commercially available canine specific enzyme linked 
immunosorbent assays may therefore be warranted to identify this protein in 
further serum or tissue samples from dogs with HG MCT. 
This technique of proteomic evaluation identified a large number of proteins 
with confidence and within expected protein bands. The MOWSE score cut-off 
employed may result in not identifying some proteins present in the samples, 
but was used to ensure confidence in the results. 
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The limitations of this study are the small sample sizes which could result in 
both type one and two error.  Not every protein band identified from the 2D-
PAGE was submitted for MS analysis. Doing so may have allowed identification of 
the same protein in multiple dogs within the same group, increasing the 
reliability of the published data. Additional proteins may also have been 
identified as a result. The HG MCT group contained tumours which were 
significantly larger and more dogs with a higher tumour stage than the LG MCT, 
therefore proteomic changes may be a result of increasing tumour size and stage 
alone. However, the dog with most protein bands identified (dog 9), had a 
tumour below the median tumour size for HG MCT and had stage I disease.  
Additionally, the LG MCT dog with stage II disease (dog 5) had the fewest 
proteins bands (9).  
The control group had a significantly younger age than the LG and HG groups. 
Younger dogs are less likely to have disease and therefore some of the proteins 
identified may be as a consequence of comorbidities in the LG MCT and HG MCT 
populations. Significant comorbidities resulted in exclusion from the study 
population; any comorbidities affecting the results would therefore have been 
subclinical. Also, increasing age was not found to influence 1D-SPE results in 
healthy dogs (Tappin et al ., 2011). Ideally, age matched controls would be used 
in any future research.  
Finally, it is not known whether the proteomic alterations identified are 
released from the MCT or transcribed as part of an associated inflammatory 
reaction. The serum proteins identified in the serum of dogs with HG MCT were 
not identified in a previous proteomic analysis of MCT tissue (Schlieben et al ., 
2012), suggesting that they may be an inflammatory response. If the nature of 
an inflammatory response was specific however, it would not preclude use as a 
biomarker.  
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5 Conclusions 
5.1 Neutrophil to lymphocyte ratio 
Within this population of dogs, the NLR was a good discriminatory tool to select 
HG MCTs prior to histopathological assessment. The ratio was found to be more 
useful than either of its constituent parts used alone. A cut-off value of 5.67 
was selected which was highly sensitive for detection of HG tumours, ensuring 
that dogs with a disease with an expected aggressive clinical course were not 
undertreated. This biomarker may have a clinical application, such as deciding 
on the usefulness or extent of staging or optimal treatment regimen, including 
planned surgical margins. The limitations of this study however, mean that 
further validation of the threshold value is recommended in further prospective 
case series prior to widespread clinical use. Analysis of its utility as a prognostic 
marker could also be considered. The cut-off value chosen here did result in 
many low grade tumours being incorrectly classified. One area worthy of further 
research would be a comparison of the clinical course and prognosis of those LG 
MCT with a NLR above and below the cut-off value. NLR has previously been 
identified as a useful tool to differentiate between benign and malignant soft 
tissue tumours (Macfarlane et al ., 2015). As in human neoplasia, it is likely that 
this biomarker could be useful in other difficult clinical situations, such as 
determining prognosis within a specific subset of dogs with lymphoma. 
5.2 Serum protein electrophoresis 
Significant changes were identified in the serum proteome of dogs with HG 
MCTs. Using 1D-SPE, these included an increase in the α-2 and β-1 fractions 
when compared to healthy controls. The concentration of α-2  proteins was also 
increased in dogs with HG MCT compared to those with LG MCTs. For this finding 
to be clinically significant 1D-SPE would have to be compared with a larger 
number of cases. 
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Using 1D-SPE combined with PAGE, 16 proteins mainly from the α-2 fraction  
were identified in the serum of dogs with MCTs which were not identified in 
healthy control dogs. Identified changes may reflect an inflammatory response 
to the tumour or may be produced by the MCT and contribute to a more 
aggressive phenotype. Many of these proteins, such as α-1-antiproteinase, α-2-
HS-glycoprotein, leucine-rich α-2-glycoprotein, plasma protease C1 inhibitor and 
pregnancy zone protein have been identified in the serum of human patients 
with various neoplastic conditions and are used as biomarkers for these. Further 
investigation, initially focussed on identifying these proteins from the same 
protein band in a larger group of dogs with MCTs would be useful. If proteins 
were identified in other dogs with MCTs, then future work should be directed at 
attempting to quantify these proteins. Inter-α-trypsin inhibitor heavy chain H1 
looks like the more promising target for further investigation, due to its 
production within mast cells (Bourguignon et al ., 1999). 
It is hoped that results of this investigation will stimulate further research to 
identify and quantify specific proteins in larger cohorts of dogs with MCTs. This 
may identify biomarkers which could be used to prognosticate, guide treatment 
decisions, identify therapeutic targets or improve understanding of the 
pathogenesis of MCTs.  
The method of protein identification and separation used has proved to be useful 
to identify potential biomarkers in canine MCTs and also in lymphoma. It is 
encouraging that two independent studies have identified the same proteins in 
bands at the same location on 2D-PAGE gels in both cancers and in normal dogs. 
This technique could therefore be used to identify biomarkers in other canine 
tumour types. In particular, much research has been done on identifying 
biomarkers in canine mammary cancer (Pena et al ., 2014; Estrela-Lima et al ., 
2016; Raposo et al ., 2016) and further identification of serum biomarkers may 
be a powerful tool for this tumour type.  
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Breed Sex Neuter Age 
MCT 
Grade Neutrophil Lymphocyte NLR Albumin Globulin AGR 
Clinical 
signs Size Location 
WHO 
Stage 
Lymph Node 
Metastasis 
Boxer F N 7 Low 3.20 2.25 1.42 30 36 0.83 No 9 Multiple 3 No 
Beagle F N 6 Low 3.64 1.38 2.64 29 29 1 No 58 Multiple 3 No 
Labrador 
Retriever M N 9 Low 6.61 2.32 2.85 27 35 0.77 No 40 Multiple 3 No 
West 
Highland 
White Terrier M E 4 Low 6.68 2.26 2.95 31 34 0.91 No  Head/Neck 1 No 
Labrador 
Retriever M N 4 Low 5.97 1.99 3 33 30 1.1 No 16 Extremity 1 No 
Boxer F N 3 Low 6.08 2.03 3 33 33 1 No 8 Head/Neck 1 No 
Crossbreed M N 12 Low 6.64 2.03 3.27 35 32 1.09 Yes 10 Extremity 1 No 
Boxer M E 5 Low 5.71 1.68 3.4 33 33 1 No 25 Multiple 3 No 
Boxer M N 5 Low 3.71 1.09 3.4 29 37 0.78 No 6 Extremity 1 No 
Golden 
Retriever M N 11 Low 4.18 1.21 3.45 28 29 0.97 No 25 Extremity 1 No 
Border Collie M N 1 Low 12.01 3.25 3.7 29 36 0.81 No 6 Head/Neck 1 No 
Staffordshire 
Bull Terrier F N 10 Low 4.26 1.15 3.7 31 35 0.89 No 22 Head/Neck 1 No 
Labrador 
Retriever F E 5 Low 8.47 2.17 3.89 30 36 0.83 No 10 Head/Neck 1 No 
Golden 
Retriever F N 6 Low 7.65 1.86 4.12 31 35 0.89 No 20 Head/Neck 1 No 
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Boxer M N 5 Low 6.42 1.49 4.3 27 38 0.71 No 21 Head/Neck 2 Yes 
Golden 
Retriever F N 10 Low 6.88 1.59 4.33 32 33 0.97 No 40 Multiple 3 No 
Labrador 
Retriever M E 7 Low 7.18 1.59 4.53 34 29 1.17 No 9 Head/Neck 1 No 
Crossbreed F E 6 Low 6.36 1.38 4.63 33 34 0.97 No 20 Extremity 1 No 
Miniature 
Schnauzer M N 4 Low 5.51 1.18 4.69 36 38 0.95 Yes 20 Extremity 1 No 
Labrador 
Retriever F N 11 Low 4.44 0.92 4.8 32 30 1.07 No 12 Other 1 No 
Staffordshire 
Bull Terrier M E 9 Low 3.76 0.77 4.87 32 28 1.14 No 40 Multiple 3 No 
Crossbreed F N 8 Low 6.41 1.25 5.13 32 36 0.89 No 12 Head/Neck 1 No 
Golden 
Retriever F N 6 Low 6.33 1.19 5.33 29 31 0.94 No 8 Extremity 1 No 
Crossbreed F N 11 Low 6.79 1.22 5.57 32 31 1.03 No 15 Extremity 1 No 
Pyrenean 
Mountain Dog F N 5 Low 6.86 1.22 5.62 33 31 1.06 No  Extremity 2 Yes 
Boxer M N 7 Low 5.55 0.98 5.64 31 30 1.03 No 45 Multiple 3 No 
Labrador 
Retriever F E 2 Low 9.94 1.72 5.79 30 29 1.03 No 8 Head/Neck 1 No 
Labrador 
Retriever F N 7 Low 7.77 1.31 5.92 33 30 1.1 No 20 Head/Neck 1 No 
Vizsla M E 2 Low 7.30 1.20 6.08 32 43 0.74 No 40 Extremity 1 No 
Springer 
Spaniel F N 11 Low 6.29 1.00 6.31 32 40 0.8 No 20 Head/Neck 1 No 
Boxer M N 7 Low 8.93 1.37 6.5 31 36 0.86 No 15 Head/Neck 1 No 
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Crossbreed F N 8 Low 10.35 1.59 6.5 32 40 0.8 Yes 53 Extremity 2 Yes 
Boxer M N 4 Low 4.80 0.73 6.58 28 36 0.78 No 30 Extremity 1 No 
Boxer M N 9 Low 4.80 0.73 6.58 28 36 0.78 No  Extremity 1 No 
Boxer M E 5 Low 6.11 0.93 6.58 31 31 1 No 25 Extremity 1 No 
Labrador 
Retriever M N 9 Low 5.92 0.90 6.58 28 34 0.82 No 30 Extremity 1 No 
Labrador 
Retriever M E 6 Low 7.82 1.17 6.68 34 29 1.17 No 9 Extremity 1 No 
Labrador 
Retriever F E 9 Low 6.99 1.04 6.75 32 30 1.07 No 20 Other 1 No 
Labrador 
Retriever F N 7 Low 8.42 1.25 6.75 32 28 1.14 No 45 Extremity 2 Yes 
Crossbreed M N 8 Low 8.47 1.26 6.75 29 29 1 No 43 Extremity 2 Yes 
Boxer M N 4 Low 8.69 1.27 6.83 32 37 0.86 No 32 Head/Neck 1 No 
Springer 
Spaniel M N 9 Low 6.16 0.88 7 32 34 0.94 No 80 Extremity 1 No 
Golden 
Retriever F N 6 Low 6.79 0.95 7.16 31 35 0.89 Yes 24 Other 1 No 
Boxer F N 4 Low 5.31 0.65 8.2 34 38 0.89 No 50 Multiple 3 No 
Anatolian 
Shepherd M N 8 Low 6.32 0.74 8.5 33 31 1.06 No 30 Other 1 No 
Labrador 
Retriever F E 7 Low 8.26 0.96 8.59 31 33 0.94 No 25 Other 1 No 
Golden 
Retriever M E 9 Low 8.81 1.02 8.6 30 32 0.94 No 35 Extremity 2 Yes 
Boxer M E 8 Low 6.54 0.74 8.89 32 35 0.91 No 10 Extremity 1 No 
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Labrador 
Retriever M N 7 High 5.13 1.34 3.83 35 32 1.09 No 13 Head/Neck 1 No 
Crossbreed M N 12 High 3.62 0.78 4.63 32 34 0.94 No 40 Other 2 Yes 
Labrador 
Retriever F N 10 High 5.89 1.04 5.69    Yes 20 Extremity 1 No 
Labrador 
Retriever M N 13 High 7.66 1.15 6.67 29 34 0.85 Yes 20 Head/Neck 2 Yes 
Labrador 
Retriever M N 10 High 6.91 0.89 7.8 21 27 0.78 No 40 Other 1 No 
Jack Russell 
Terrier M E 9 High 8.32 1.02 8.2 25 32 0.78 No 90 Extremity 2 Yes 
Crossbreed F N 14 High 9.58 1.10 8.7 33 33 1 No 60 Extremity 2 Yes 
Staffordshire 
Bull Terrier M E 5 High 7.13 0.78 9.15 33 34 0.97 No 40 Other 1 No 
Labrador 
Retriever M N 8 High 8.98 0.86 10.5 27 45 0.6 No 32 Other 1 No 
Crossbreed M N 6 High 8.50 0.78 10.91 34 36 0.94 No 12 Multiple 3 No 
Labrador 
Retriever M E 7 High 13.36 0.78 17.21 29 31 0.94 Yes 140 Other 2 Yes 
Lhasa Apso F E 10 High 15.18 0.85 17.8 27 41 0.66 Yes 30 Head/Neck 1 No 
Crossbreed F N 9 High 10.34 0.36 28.63 36 42 0.86 No 25 Extremity 1 No 
Labrador 
Retriever M E 12 High 5.96 0.21 29.07 26 36 0.72 No 85 Head/Neck 2 Yes 
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Appendix 1: Information of all dogs which met inclusion criteria. M=male, F=female, E=entire, N=neutered, 
Neutrophil=neutrophil concentration (x109/l), Lymphocyte=lymphocyte concentration (x109/l), Albumin=albumin 
concentration (g/l), Globulin=globulin (g/l), Size in millimetres.  
